Drug Targets - Has CLUE.IO Entries

Molecular Background Data Compounds Data

Targets with CLUE.IO data (52):
Number of Compounds	512
AVG Compounds Per Target	9.85
Preclinical Compounds	136
Phase 1 Compounds	61
Phase 2 Compounds	80
Phase 3 Compounds	55
Launched Compounds	176
Withdrawn Compounds	4
CDK4, CDK6, COL1A1, EGF, EGFR, ERBB3, ITGA2, ITGA5, ITGAV, ITGB5, KDM6A, KRAS, LGALS1, MDM2, PARP1, PKM, PLAU, PLAUR, TRK, VCAN, CDH2, EGLN2, MAPT, PAK3, PAK7, RET, TUBB3, ALDH2, ANXA1, BCAT1, BIRC3, CD44, CES1, CTSS, CXCR2, CYP3A5, FCGR1A, IDH2, ITGB6, MMP7, MYC, ROS1, AR, ATR, CHEK1, CXCL2, CXCR4, NOS1, NOS2, PIK3CA, VCAM1, WEE1
Targets with no CLUE.IO data (91):
ACTN1, ADAM10, APLP2, APOL1, BST2, CALU, COL1A2, COL3A1, COL5A1, COL6A3, CTNNA1, FBN1, FN1, IFI27, IGFBP3, MATN3, MFGE8, MSLN, MX1, MX2, P53, PD-1, SDC1, SPARC, TGFB, TIMP1, AMH, CCNA1, CHGA, COL9A3, CXXC4, DLK1, DLL3, DNAJC6, DPYSL4, FGF5, FLJ10474, FOXA2, GNG4, GRP, ID4, ISL1, L1CAM, MAP1B, NCAM1, NKX2-1, RTN1, SMAD9, SYP, ZIC2, ANXA3, CD27, CD70, FGFBP1, FOXI1, GPR126, ITGAM, ITGB4, KRT17, KRT5, LRMP, MAGEA4, PGC, PRAME, PVR, RAB27B, SPP1, TP63, VSNL1, YBX3, AKT, CD137, CD40, CD73, CTLA-4, Dectin1, IL-12A, IL-2, IL-6, IL1R, IL2RB, LAG-3, LIV-1, M-CSF, MEK1, mTOR, Nectin-4, Plk4, ROR2, TNC, TNFRSF4

HUGO	RP	KP	SI	MF	SL	BP
ALDH2	2	16	34	8	3	6
ANXA1	5	0	16	7	25	51
AR	6	4	126	18	8	50
ATR	0	0	0	0	0	0
BCAT1	1	9	8	5	2	5
BIRC3	10	16	69	6	6	18
CD44	6	6	69	3	14	22
CDH2	4	2	36	8	24	32
CDK4	17	28	86	7	13	21
CDK6	8	23	48	7	9	31
CES1	2	1	9	4	5	16
CHEK1	10	6	94	7	11	29
COL1A1	20	11	36	6	9	45
CTSS	6	5	16	6	11	15
CXCL2	3	14	25	2	2	8
CXCR2	3	7	34	6	10	16
CXCR4	4	13	92	12	14	40
CYP3A5	2	6	39	10	2	10
EGF	31	31	121	5	8	35
EGFR	35	48	215	19	26	61
EGLN2	1	3	8	6	3	8
ERBB3	15	7	52	12	9	24
FCGR1A	0	0	0	0	1	0
IDH2	2	10	14	3	5	6
ITGA2	7	14	59	10	10	43
ITGA5	6	17	48	6	12	21
ITGAV	11	16	122	12	22	36
ITGB5	6	10	43	3	7	8
ITGB6	4	8	31	3	9	24
KDM6A	2	1	20	5	4	5
KRAS	0	0	0	2	1	1
LGALS1	2	0	1	3	7	10
MAPT	2	4	56	23	26	56
MDM2	13	25	153	16	9	39
MMP7	5	2	26	5	4	7
MYC	16	34	178	12	8	96
NOS1	3	13	39	14	18	35
NOS2	5	19	81	11	10	31
PAK3	13	10	55	7	6	17
PAK7	5	8	36	4	6	13
PARP1	8	5	53	15	13	47
PIK3CA	57	106	258	13	10	50
PKM	2	12	67	9	13	5
PLAU	2	6	32	1	11	16
PLAUR	3	2	48	5	14	13
RET	2	5	47	6	10	39
ROS1	0	0	2	5	3	9
TRK	10	11	83	13	14	48
TUBB3	30	10	5	4	9	4
VCAM1	4	9	31	3	15	28
VCAN	13	1	50	5	10	7
WEE1	7	2	14	6	4	6

Target	PRC	PH1	PH2	PH3	LNC	PM	PCH	CHE	DB
ALDH2	2	2	1	0	4	1058	6	6	5
ANXA1	0	0	0	0	2	400	1	2	2
AR	6	9	8	5	25	5148	32	47	37
ATR	6	1	2	1	1	371	5	10	5
BCAT1	0	0	0	2	1	467	0	3	3
BIRC3	2	2	1	0	0	22	4	5	2
CD44	0	0	0	0	2	400	1	2	1
CDH2	0	0	1	0	0	4	0	0	0
CDK4	9	6	7	1	3	937	7	25	15
CDK6	3	4	5	0	3	1233	8	14	10
CES1	2	1	0	2	3	504	6	8	5
CHEK1	12	3	4	1	0	325	8	18	11
COL1A1	0	0	0	0	1	48	0	1	1
CTSS	2	1	0	0	1	234	2	3	0
CXCL2	0	0	0	1	0	109	0	1	1
CXCR2	3	0	3	1	0	176	3	6	2
CXCR4	5	0	2	1	2	438	4	8	4
CYP3A5	1	1	2	4	92	18998	46	98	92
EGF	0	0	1	0	0	190	1	1	1
EGFR	27	10	17	11	13	3253	37	74	43
EGLN2	2	0	1	3	0	120	3	4	3
ERBB3	1	1	1	0	1	210	2	4	3
FCGR1A	0	0	0	0	1	167	0	1	1
IDH2	1	0	0	0	0	1	1	1	0
ITGA2	2	0	1	0	0	8	2	0	1
ITGA5	0	0	1	0	0	3	1	0	0
ITGAV	1	2	1	1	0	288	2	2	1
ITGB5	0	0	1	1	0	88	2	1	1
ITGB6	0	1	0	0	0	0	0	0	0
KDM6A	3	0	0	0	0	2	2	3	0
KRAS	2	0	1	1	0	165	2	2	2
LGALS1	0	1	0	0	1	200	1	2	1
MAPT	0	0	0	1	4	807	2	5	3
MDM2	5	5	2	1	0	468	1	11	7
MMP7	0	0	0	1	0	114	0	1	1
MYC	1	2	0	0	0	5	1	3	0
NOS1	7	1	1	2	4	899	8	13	9
NOS2	11	3	3	3	7	2087	14	25	17
PAK3	1	0	0	0	0	0	1	1	0
PAK7	0	1	0	0	0	2	1	1	1
PARP1	8	0	5	4	6	1575	9	19	14
PIK3CA	12	8	12	4	5	1095	19	37	29
PKM	2	0	0	0	1	106	0	2	1
PLAU	2	0	1	0	2	404	2	3	3
PLAUR	1	0	0	0	0	0	1	1	0
RET	4	2	3	6	9	2163	7	24	19
ROS1	0	0	1	0	5	633	3	4	3
TRK	0	0	1	0	0	7	0	0	0
TUBB3	0	0	0	0	5	1000	3	5	5
VCAM1	0	0	1	1	0	32	0	2	2
VCAN	0	0	0	0	1	200	0	1	0
WEE1	2	0	1	0	0	40	0	3	2

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	Phase 2	From PubMed: PubMed 21745173 PubMed 10888035 PubMed 16293603 CLUE.IO ClinicalTrials	CHEMBL574737 PubChem: 3078519 DB1933
abemaciclib	CDK inhibitor	Launched	From PubMed: PubMed 28968163 PubMed 33369721 PubMed 32954927 FDA Labels: Verzenio From EMA: Verzenios (PDF) CLUE.IO DailyMed	CHEMBL3301610 PubChem: 46220502 DB12001
alvocidib	CDK inhibitor	Phase 2	From PubMed: PubMed 26998706 PubMed 32998965 PubMed 26521988 CLUE.IO ClinicalTrials	CHEMBL428690 PubChem: 5287969 DB03496
AMG-925	CDK inhibitor, FLT3 inhibitor	Phase 1	From PubMed: PubMed 30514344 CLUE.IO Unexpected Source	CHEMBL3237719 PubChem:
arcyriaflavin-a	CDK inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL268368 PubChem: 5327723
AT-7519	CDK inhibitor	Phase 2	From PubMed: PubMed 34062779 PubMed 33095286 PubMed 21325451 CLUE.IO ClinicalTrials	CHEMBL445813 PubChem: 11338033 DB08142
FN-1501	tyrosine kinase inhibitor	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL4077071 PubChem: 72195175
GF109203X	PKC inhibitor	Preclinical	From PubMed: PubMed 21944247 PubMed 11004713 PubMed 10909084 CLUE.IO	CHEMBL7463 PubChem: 2396 DB03777
indirubin	CDK inhibitor, glycogen synthase kinase inhibitor	Phase 2/Phase 3	From PubMed: PubMed 26457112 PubMed 25887337 PubMed 12685829 CLUE.IO ClinicalTrials	CHEMBL1276127 PubChem??indirubin??
indirubin-3-monoxime	CDK inhibitor, glycogen synthase kinase inhibitor	Preclinical	From PubMed: PubMed 29678389 PubMed 10788588 CLUE.IO	CHEMBL216543 PubChem??indirubin-3-monoxime?? DB02052
NSC-625987	CDK inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL1331734 PubChem??NSC-625987??
ON123300	CDK inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL3115681 PubChem??ON123300??
P276-00	CDK inhibitor	Phase 2	From PubMed: PubMed 34094661 PubMed 25816934 PubMed 22928661 CLUE.IO ClinicalTrials	CHEMBL3969723 PubChem??P276-00??
palbociclib	CDK inhibitor	Launched	From PubMed: PubMed 27959613 PubMed 33369721 PubMed 31643218 FDA Labels: Ibrance Ibrance From EMA: Ibrance (PDF) CLUE.IO FDA Orange Book: palbociclib	CHEMBL189963 PubChem??palbociclib?? DB09073
PF-06873600	CDK inhibitor	Phase 2	From PubMed: No search result CLUE.IO ClinicalTrials	PubChem??PF-06873600??
PHA-793887	CDK inhibitor	Phase 1	From PubMed: PubMed 21368575 PubMed 21200142 CLUE.IO ClinicalTrials	CHEMBL1230607 PubChem??PHA-793887?? DB12686
PHA-848125	CDK inhibitor, growth factor receptor inhibitor	Phase 2	From PubMed: PubMed 22160853 PubMed 28424962 CLUE.IO ClinicalTrials	CHEMBL564829 PubChem??PHA-848125??
purvalanol-A	CDK inhibitor	Preclinical	From PubMed: PubMed 26081925 PubMed 35533805 CLUE.IO	CHEMBL23327 PubChem??purvalanol-A?? DB04751
purvalanol-B	tyrosine kinase inhibitor	Preclinical	From PubMed: PubMed 15023358 PubMed 18051438 CLUE.IO	CHEMBL23254 PubChem??purvalanol-B?? DB02733
R547	CDK inhibitor	Phase 1	From PubMed: PubMed 10959826 PubMed 19755512 PubMed 19640487 CLUE.IO PubMed	CHEMBL384304 PubChem??R547?? DB08094
RGB-286638	CDK inhibitor	Phase 1	From PubMed: PubMed 34094661 PubMed 26766294 PubMed 25024258 CLUE.IO ClinicalTrials	CHEMBL3545083 PubChem??RGB-286638??
ribociclib	CDK inhibitor	Launched	From PubMed: PubMed 33369721 PubMed 29718092 PubMed 31826360 From EMA: Kisqali (PDF) CLUE.IO DailyMed	CHEMBL3545110 PubChem??ribociclib?? DB11730
ryuvidine	histone lysine methyltransferase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL290904 PubChem??ryuvidine??
SU9516	CDK inhibitor	Preclinical	From PubMed: PubMed 15964238 CLUE.IO	CHEMBL258805 PubChem??SU9516?? DB03428
trilaciclib	CDK inhibitor	Phase 2	From PubMed: PubMed 33861388 PubMed 31504118 PubMed 33123968 FDA Labels: Cosela CLUE.IO ClinicalTrials	CHEMBL3894860 PubChem??trilaciclib?? DB15442
voruciclib	CDK9 inhibitor	Phase 1	From PubMed: PubMed 30508677 PubMed 32407139 CLUE.IO ClinicalTrials	CHEMBL3905910 PubChem??voruciclib?? DB15157

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P11802}

Subcellular Locations ^{Source UniProt P11802}

Biological Processes ^{Source UniProt P11802}

KEGG hsa:1019 ^{Source UniProt P11802}

Reactome Pathways ^{Source UniProt P11802}

R-HSA-187577, SCF(Skp2)-mediated degradation of p27/p21
R-HSA-2559580, Oxidative Stress Induced Senescence
R-HSA-2559582, Senescence-Associated Secretory Phenotype (SASP)
R-HSA-2559585, Oncogene Induced Senescence
R-HSA-3214858, RMTs methylate histone arginines
R-HSA-381340, Transcriptional regulation of white adipocyte differentiation
R-HSA-69231, Cyclin D associated events in G1
R-HSA-75815, Ubiquitin-dependent degradation of Cyclin D
R-HSA-8849470, PTK6 Regulates Cell Cycle
R-HSA-8878166, Transcriptional regulation by RUNX2
R-HSA-912446, Meiotic recombination
R-HSA-9616222, Transcriptional regulation of granulopoiesis
R-HSA-9630791, Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
R-HSA-9630794, Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
R-HSA-9632697, Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
R-HSA-9632700, Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
R-HSA-9661069, Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	Phase 2	From PubMed: PubMed 21745173 PubMed 10888035 PubMed 16293603 CLUE.IO ClinicalTrials	CHEMBL574737 PubChem: 3078519 DB1933
abemaciclib	CDK inhibitor	Launched	From PubMed: PubMed 28968163 PubMed 33369721 PubMed 32954927 FDA Labels: Verzenio From EMA: Verzenios (PDF) CLUE.IO DailyMed	CHEMBL3301610 PubChem: 46220502 DB12001
alvocidib	CDK inhibitor	Phase 2	From PubMed: PubMed 26998706 PubMed 32998965 PubMed 26521988 CLUE.IO ClinicalTrials	CHEMBL428690 PubChem: 5287969 DB03496
AMG-925	CDK inhibitor, FLT3 inhibitor	Phase 1	From PubMed: PubMed 30514344 CLUE.IO Unexpected Source	CHEMBL3237719 PubChem:
apigenin	casein kinase inhibitor, cell proliferation inhibitor	Preclinical	From PubMed: PubMed 30875872 PubMed 32059077 PubMed 32660399 CLUE.IO	CHEMBL28 PubChem: 5280443 DB07352
AT-7519	CDK inhibitor	Phase 2	From PubMed: PubMed 34062779 PubMed 33095286 PubMed 21325451 CLUE.IO ClinicalTrials	CHEMBL445813 PubChem: 11338033 DB08142
chrysin	breast cancer resistance protein inhibitor	Phase 1	From PubMed: PubMed 31472146 PubMed 34198618 PubMed 29161583 CLUE.IO PubMed	CHEMBL117 PubChem: 5281607 DB15581
fisetin	Aurora kinase inhibitor	Preclinical	From PubMed: PubMed 31064104 PubMed 33473265 PubMed 27671819 CLUE.IO	CHEMBL31574 PubChem: 5281614 DB07795
FN-1501	tyrosine kinase inhibitor	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL4077071 PubChem: 72195175
ON123300	CDK inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL3115681 PubChem??ON123300??
palbociclib	CDK inhibitor	Launched	From PubMed: PubMed 27959613 PubMed 33369721 PubMed 31643218 FDA Labels: Ibrance Ibrance From EMA: Ibrance (PDF) CLUE.IO FDA Orange Book: palbociclib	CHEMBL189963 PubChem??palbociclib?? DB09073
PF-06873600	CDK inhibitor	Phase 2	From PubMed: No search result CLUE.IO ClinicalTrials	PubChem??PF-06873600??
RGB-286638	CDK inhibitor	Phase 1	From PubMed: PubMed 34094661 PubMed 26766294 PubMed 25024258 CLUE.IO ClinicalTrials	CHEMBL3545083 PubChem??RGB-286638??
ribociclib	CDK inhibitor	Launched	From PubMed: PubMed 33369721 PubMed 29718092 PubMed 31826360 From EMA: Kisqali (PDF) CLUE.IO DailyMed	CHEMBL3545110 PubChem??ribociclib?? DB11730
trilaciclib	CDK inhibitor	Phase 2	From PubMed: PubMed 33861388 PubMed 31504118 PubMed 33123968 FDA Labels: Cosela CLUE.IO ClinicalTrials	CHEMBL3894860 PubChem??trilaciclib?? DB15442

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt Q00534}

Subcellular Locations ^{Source UniProt Q00534}

Biological Processes ^{Source UniProt Q00534}

KEGG hsa:1021 ^{Source UniProt Q00534}

Reactome Pathways ^{Source UniProt Q00534}

R-HSA-2559580, Oxidative Stress Induced Senescence
R-HSA-2559582, Senescence-Associated Secretory Phenotype (SASP)
R-HSA-2559585, Oncogene Induced Senescence
R-HSA-69231, Cyclin D associated events in G1
R-HSA-8934593, Regulation of RUNX1 Expression and Activity
R-HSA-9630794, Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
R-HSA-9632700, Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
R-HSA-9661069, Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
halofuginone	collagenase inhibitor	Launched	From PubMed: PubMed 28986385 PubMed 21117034 PubMed 25569515 From EMA: Kriptazen (PDF) CLUE.IO drugs.com	CHEMBL1199540 PubChem??halofuginone?? DB04866

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P02452}

Subcellular Locations ^{Source UniProt P02452}

Biological Processes ^{Source UniProt P02452}

KEGG hsa:1277 ^{Source UniProt P02452}

Reactome Pathways ^{Source UniProt P02452}

R-HSA-114604, GPVI-mediated activation cascade
R-HSA-1442490, Collagen degradation
R-HSA-1474244, Extracellular matrix organization
R-HSA-1650814, Collagen biosynthesis and modifying enzymes
R-HSA-198933, Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-2022090, Assembly of collagen fibrils and other multimeric structures
R-HSA-202733, Cell surface interactions at the vascular wall
R-HSA-216083, Integrin cell surface interactions
R-HSA-2214320, Anchoring fibril formation
R-HSA-2243919, Crosslinking of collagen fibrils
R-HSA-3000170, Syndecan interactions
R-HSA-3000171, Non-integrin membrane-ECM interactions
R-HSA-3000178, ECM proteoglycans
R-HSA-3000480, Scavenging by Class A Receptors
R-HSA-430116, GP1b-IX-V activation signalling
R-HSA-75892, Platelet Adhesion to exposed collagen
R-HSA-76009, Platelet Aggregation (Plug Formation)
R-HSA-8874081, MET activates PTK2 signaling
R-HSA-8940973, RUNX2 regulates osteoblast differentiation
R-HSA-8948216, Collagen chain trimerization

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
gossypol	BCL inhibitor, MCL1 inhibitor	Phase 2	From PubMed: PubMed 34703914 PubMed 28545375 PubMed 26803304 CLUE.IO ClinicalTrials	CHEMBL51483 PubChem: 3503 DB13044

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P01133}

Subcellular Locations ^{Source UniProt P01133}

Biological Processes ^{Source UniProt P01133}

KEGG hsa:1950 ^{Source UniProt P01133}

Reactome Pathways ^{Source UniProt P01133}

R-HSA-114608, Platelet degranulation
R-HSA-1227986, Signaling by ERBB2
R-HSA-1236382, Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
R-HSA-1236394, Signaling by ERBB4
R-HSA-1250196, SHC1 events in ERBB2 signaling
R-HSA-1251932, PLCG1 events in ERBB2 signaling
R-HSA-1257604, PIP3 activates AKT signaling
R-HSA-177929, Signaling by EGFR
R-HSA-179812, GRB2 events in EGFR signaling
R-HSA-180292, GAB1 signalosome
R-HSA-180336, SHC1 events in EGFR signaling
R-HSA-182971, EGFR downregulation
R-HSA-1963640, GRB2 events in ERBB2 signaling
R-HSA-1963642, PI3K events in ERBB2 signaling
R-HSA-212718, EGFR interacts with phospholipase C-gamma
R-HSA-2219530, Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-5637810, Constitutive Signaling by EGFRvIII
R-HSA-5638303, Inhibition of Signaling by Overexpressed EGFR
R-HSA-5673001, RAF/MAP kinase cascade
R-HSA-6785631, ERBB2 Regulates Cell Motility
R-HSA-6811558, PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-8847993, ERBB2 Activates PTK6 Signaling
R-HSA-8856825, Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828, Clathrin-mediated endocytosis
R-HSA-8863795, Downregulation of ERBB2 signaling
R-HSA-9009391, Extra-nuclear estrogen signaling
R-HSA-9013507, NOTCH3 Activation and Transmission of Signal to the Nucleus
R-HSA-9634638, Estrogen-dependent nuclear events downstream of ESR-membrane signaling
R-HSA-9664565, Signaling by ERBB2 KD Mutants
R-HSA-9665348, Signaling by ERBB2 ECD mutants
R-HSA-9665686, Signaling by ERBB2 TMD/JMD mutants

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
AEE788	EGFR inhibitor, VEGFR inhibitor	Phase 1/Phase 2	From PubMed: PubMed 21984222 PubMed 23014528 PubMed 22392572 CLUE.IO ClinicalTrials	CHEMBL587723 PubChem: 10297043 DB12558
afatinib	EGFR inhibitor	Launched	From PubMed: PubMed 29999905 PubMed 30069769 PubMed 28295308 FDA Labels: Gilotrif From EMA: Giotrif (PDF) CLUE.IO FDA Orange Book: afatinib dimaleate	CHEMBL1173655 PubChem: 10184653 DB08916
AG-1024	insulin growth factor receptor inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL2218926 PubChem: 2044
AG-490	EGFR inhibitor, JAK inhibitor	Preclinical	From PubMed: PubMed 20156166 PubMed 12528768 PubMed 15930886 CLUE.IO	CHEMBL56543 PubChem: 5328779
alvocidib	CDK inhibitor	Phase 2	From PubMed: PubMed 26998706 PubMed 32998965 PubMed 26521988 CLUE.IO ClinicalTrials	CHEMBL428690 PubChem: 5287969 DB03496
AP26113	ALK tyrosine kinase receptor inhibitor	Phase 2	From PubMed: PubMed 30280657 PubMed 32780660 PubMed 34537440 CLUE.IO ClinicalTrials	CHEMBL3397300 PubChem: 57390074
ARRY-334543	EGFR inhibitor	Phase 2/Phase 3	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL2103842 PubChem: 42642648 DB05944
AST-1306	EGFR inhibitor	Phase 1	From PubMed: PubMed 29856578 PubMed 24598282 PubMed 24612546 CLUE.IO PubMed	CHEMBL1947204 PubChem: 24739943
AV-412	protein tyrosine kinase inhibitor	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL2138625 PubChem: 9806229
avitinib	EGFR inhibitor	Phase 2	From PubMed: PubMed 33338652 PubMed 30500458 PubMed 34558640 CLUE.IO ClinicalTrials	PubChem: 72734520 DB15327
AVL-292	Bruton's tyrosine kinase (BTK) inhibitor	Phase 2	From PubMed: PubMed 24357428 PubMed 22612424 CLUE.IO ClinicalTrials	CHEMBL3301625 PubChem: 59174488 DB11764
AZ5104	EGFR inhibitor	Preclinical	From PubMed: PubMed 28009438 PubMed 34419684 PubMed 29683562 CLUE.IO	CHEMBL3353411 PubChem: 71496460
AZD3759	EGFR inhibitor	Phase 2/Phase 3	From PubMed: PubMed 29056570 PubMed 28625644 PubMed 26898616 CLUE.IO ClinicalTrials	CHEMBL3623290 PubChem: 78209992 DB14795
AZD8931	EGFR inhibitor	Phase 2	From PubMed: PubMed 27654971 PubMed 24875132 PubMed 23589215 CLUE.IO ClinicalTrials	CHEMBL2408045 PubChem: 11488320 DB12183
BIBU-1361	EGFR inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL1358485 PubChem: 17756796
BIBX-1382	EGFR inhibitor	Phase 1	From PubMed: PubMed 12008195 CLUE.IO ClinicalTrials	CHEMBL258940 PubChem: 6918508 DB12966
BMS-599626	EGFR inhibitor, protein tyrosine kinase inhibitor	Phase 1	From PubMed: PubMed 21576284 PubMed 15857287 CLUE.IO ClinicalTrials	CHEMBL1645462 PubChem: 10437018 DB12318
BMS-690514	EGFR inhibitor, VEGFR inhibitor	Phase 2	From PubMed: PubMed 22031621 PubMed 22878519 PubMed 23490650 CLUE.IO ClinicalTrials	CHEMBL3545396 PubChem: 11349170 DB11665
brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	Launched	From PubMed: PubMed 30280657 PubMed 32780660 PubMed 34537440 From EMA: Alunbrig (PDF) CLUE.IO DailyMed	CHEMBL3545311 PubChem: 68165256 DB12267
canertinib	EGFR inhibitor	Phase 3	From PubMed: PubMed 14730468 PubMed 25592338 PubMed 15142631 CLUE.IO ClinicalTrials	CHEMBL31965 PubChem: 156414 DB05424
CEP-32496	RAF inhibitor	Phase 1/Phase 2	From PubMed: PubMed 30487236 CLUE.IO ClinicalTrials	CHEMBL2029988 PubChem: 56846693 DB15068
CGP-52411	EGFR inhibitor	Preclinical	From PubMed: PubMed 15757396 CLUE.IO	CHEMBL268868 PubChem: 1697
CGP-53353	EGFR inhibitor, PKC inhibitor	Preclinical	From PubMed: PubMed 15757396 CLUE.IO	CHEMBL7939 PubChem: 6711154
chrysophanic-acid	EGFR inhibitor	Preclinical	From PubMed: PubMed 31373015 PubMed 30781696 PubMed 19796670 CLUE.IO	CHEMBL41092 PubChem: 10208
CK-101	EGFR inhibitor	Preclinical	From PubMed: No search result CLUE.IO	PubChem: 117909640
CNX-2006	EGFR inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL3985592 PubChem: 56968072
CP-547632	kinase inhibitor	Phase 2	From PubMed: PubMed 15503863 PubMed 17031646 CLUE.IO ClinicalTrials	CHEMBL253969 PubChem: 9811611 DB12962
CUDC-101	EGFR inhibitor	Phase 1	From PubMed: PubMed 25573383 PubMed 25107918 PubMed 31218726 CLUE.IO ClinicalTrials	CHEMBL598797 PubChem: 24756910 DB12174
dacomitinib	EGFR inhibitor	Launched	From PubMed: PubMed 31643328 PubMed 30372001 PubMed 28958502 FDA Labels: Vizimpro From EMA: Vizimpro (PDF) CLUE.IO DailyMed	CHEMBL2110732 PubChem: 11511120 DB11963
delphinidin	membrane permeability inhibitor	Phase 2	From PubMed: PubMed 34768930 PubMed 31557009 PubMed 34679848 CLUE.IO Integrity	CHEMBL276780 PubChem: 128853
dovitinib	EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	Phase 3	From PubMed: PubMed 34251745 PubMed 27245147 PubMed 25284004 CLUE.IO ClinicalTrials	CHEMBL522892 PubChem: 135398510 DB05928
EGF816	EGFR inhibitor	Phase 2	From PubMed: PubMed 33338652 PubMed 29377179 PubMed 27323238 CLUE.IO ClinicalTrials	CHEMBL3787344 PubChem: 72703790
erbstatin-analog	EGFR inhibitor, tyrosine kinase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL17329 PubChem: 5353609
erlotinib	EGFR inhibitor	Launched	From PubMed: PubMed 28295308 PubMed 30069756 PubMed 34388377 FDA Labels: Erlotinib Hydrochloride ERLOTINIB HYDROCHLORIDE ERLOTINIB HYDROCHLORIDE From EMA: Tarceva (PDF) CLUE.IO FDA Orange Book: erlotinib hydrochloride	CHEMBL553 PubChem: 176870 DB00530
gefitinib	EGFR inhibitor	Launched	From PubMed: PubMed 30069771 PubMed 31682542 PubMed 24794908 FDA Labels: IRESSA From EMA: Iressa (PDF) CLUE.IO FDA Orange Book: gefitinib	CHEMBL939 PubChem: 123631 DB00317
genistein	tyrosine kinase inhibitor	Phase 2/Phase 3	From PubMed: PubMed 30517965 PubMed 29065980 PubMed 34578926 CLUE.IO ClinicalTrials	CHEMBL44 PubChem: 5280961 DB01645
GW-583340	EGFR inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL453376 PubChem: 5329480
HKI-357	EGFR inhibitor	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL178654 PubChem??HKI-357?? DB13002
icotinib	EGFR inhibitor	Launched	From PubMed: PubMed 34280355 PubMed 31934888 PubMed 28945850 CLUE.IO ClinicalTrials	CHEMBL2087361 PubChem??icotinib?? DB11737
lapatinib	EGFR inhibitor	Launched	From PubMed: PubMed 30069757 PubMed 32678716 PubMed 33581774 FDA Labels: Lapatinib From EMA: Tyverb (PDF) CLUE.IO FDA Orange Book: lapatinib ditosylate	CHEMBL554 PubChem??lapatinib?? DB01259
lazertinib	tyrosine kinase inhibitor	Phase 1/Phase 2	From PubMed: PubMed 34028784 PubMed 31587882 PubMed 33338652 CLUE.IO ClinicalTrials	PubChem??lazertinib??
lidocaine	histamine receptor agonist	Launched	From PubMed: PubMed 30117019 PubMed 31900074 PubMed 29536530 From EMA: Fortacin (PDF) CLUE.IO FDA Orange Book: lidocaine, lidocaine hydrochloride	CHEMBL79 PubChem??lidocaine?? DB00281
lifirafenib	RAF inhibitor	Phase 1/Phase 2	From PubMed: PubMed 32182156 PubMed 30118796 PubMed 30599278 CLUE.IO ClinicalTrials	PubChem??lifirafenib?? DB14773
mubritinib	protein tyrosine kinase inhibitor	Phase 1	From PubMed: PubMed 34704521 PubMed 12850190 CLUE.IO ClinicalTrials	CHEMBL1614707 PubChem??mubritinib?? DB12682
naquotinib	EGFR inhibitor	Phase 3	From PubMed: PubMed 33338652 PubMed 30718357 PubMed 30649743 CLUE.IO ClinicalTrials	CHEMBL3663929 PubChem??naquotinib?? DB12036
neratinib	EGFR inhibitor	Launched	From PubMed: PubMed 32678716 PubMed 31644242 PubMed 29146401 FDA Labels: Nerlynx From EMA: Nerlynx (PDF) CLUE.IO ClinicalTrials	CHEMBL180022 PubChem??neratinib?? DB11828
olmutinib	Bruton's tyrosine kinase (BTK) inhibitor, EGFR inhibitor	Launched	From PubMed: PubMed 33434335 PubMed 33338652 PubMed 30500458 CLUE.IO Unexpected Source	CHEMBL3786343 PubChem??olmutinib?? DB13164
orantinib	FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	Phase 3	From PubMed: PubMed 28988687 PubMed 28052652 PubMed 25472913 CLUE.IO ClinicalTrials	CHEMBL274654 PubChem??orantinib?? DB12072
OSI-420	EGFR inhibitor	Preclinical	From PubMed: PubMed 31392390 PubMed 23099006 PubMed 21775215 CLUE.IO	CHEMBL3186743 PubChem??OSI-420??
osimertinib	EGFR inhibitor	Launched	From PubMed: PubMed 31564718 PubMed 31751012 PubMed 29151359 FDA Labels: TAGRISSO From EMA: Tagrisso (PDF) CLUE.IO FDA	CHEMBL3353410 PubChem??osimertinib?? DB09330
PD-153035	EGFR inhibitor	Phase 1	From PubMed: PubMed 12171571 PubMed 30129426 PubMed 12710215 CLUE.IO PubMed	CHEMBL29197 PubChem??PD-153035??
PD-158780	EGFR inhibitor	Preclinical	From PubMed: PubMed 17520578 CLUE.IO	CHEMBL53753 PubChem??PD-158780??
PD-166285	SRC inhibitor	Preclinical	From PubMed: PubMed 20406171 CLUE.IO	CHEMBL49120 PubChem??PD-166285??
PD-168393	EGFR inhibitor	Preclinical	From PubMed: PubMed 12820779 CLUE.IO	CHEMBL285063 PubChem??PD-168393?? DB07662
pelitinib	EGFR inhibitor	Phase 2	From PubMed: PubMed 30500458 PubMed 33618829 PubMed 23359171 CLUE.IO ClinicalTrials	CHEMBL607707 PubChem??pelitinib?? DB05524
PF-06459988	receptor tyrosine protein kinase inhibitor	Phase 2	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL3786098 PubChem??PF-06459988?? DB14768
PF-06747775	EGFR inhibitor	Phase 2	From PubMed: PubMed 27071706 PubMed 28526474 CLUE.IO ClinicalTrials	CHEMBL3989970 PubChem??PF-06747775??
PKI-166	EGFR inhibitor	Phase 1	From PubMed: PubMed 17615536 PubMed 12422050 PubMed 16051028 CLUE.IO PubMed	CHEMBL1963502 PubChem??PKI-166??
poziotinib	EGFR inhibitor	Phase 2	From PubMed: PubMed 31588020 PubMed 34550757 PubMed 34843401 CLUE.IO ClinicalTrials	CHEMBL3545154 PubChem??poziotinib?? DB12114
PP-121	protein tyrosine kinase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL1081312 PubChem??PP-121?? DB08052
pyrotinib	kinase inhibitor	Phase 3	From PubMed: PubMed 33581774 PubMed 30596880 PubMed 31430226 CLUE.IO ClinicalTrials	CHEMBL3647420 PubChem??pyrotinib?? DB14993
quercetin	polar auxin transport inhibitor	Launched	From PubMed: PubMed 26999194 PubMed 29127724 PubMed 33034398 FDA Labels: Quercetin Phenolic Allercetin Bread Cravings Egg Allergen Mix Formula 2 Grain and Soy Allergen Mix CLUE.IO ClinicalTrials	CHEMBL50 PubChem??quercetin?? DB04216
rociletinib	EGFR inhibitor	Phase 3	From PubMed: PubMed 26950414 PubMed 33338652 PubMed 28210165 CLUE.IO ClinicalTrials	CHEMBL3545308 PubChem??rociletinib?? DB11907
SKLB-1028	Abl kinase inhibitor, EGFR inhibitor, FLT3 inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL3678958 PubChem??SKLB-1028??
TAK-285	EGFR inhibitor	Phase 1	From PubMed: PubMed 22240796 PubMed 23817974 CLUE.IO ClinicalTrials	CHEMBL1614725 PubChem??TAK-285??
tyrphostin-AG-1478	EGFR inhibitor	Preclinical	From PubMed: PubMed 20553947 PubMed 11164186 PubMed 11313882 CLUE.IO	CHEMBL7917 PubChem??tyrphostin-AG-1478??
tyrphostin-AG-18	EGFR inhibitor, tyrosine kinase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL76904 PubChem??tyrphostin-AG-18??
tyrphostin-AG-494	EGFR inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL56731 PubChem??tyrphostin-AG-494??
tyrphostin-AG-835	protein tyrosine kinase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL261557 PubChem??tyrphostin-AG-835??
tyrphostin-AG-99	tyrosine kinase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL296407 PubChem??tyrphostin-AG-99??
vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	Launched	From PubMed: PubMed 29999926 PubMed 31643498 PubMed 25031937 FDA Labels: CAPRELSA From EMA: Caprelsa (PDF) CLUE.IO FDA Orange Book: vandetanib	CHEMBL24828 PubChem??vandetanib?? DB05294
vatalanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	Phase 3	From PubMed: PubMed 17302531 PubMed 24838014 PubMed 16882767 CLUE.IO ClinicalTrials	CHEMBL101253 PubChem??vatalanib?? DB04879
WHI-P154	JAK inhibitor	Preclinical	From PubMed: PubMed 12188892 PubMed 25268163 PubMed 11217368 CLUE.IO	CHEMBL473773 PubChem??WHI-P154??
WZ-3146	EGFR inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL1643976 PubChem??WZ-3146??
WZ-4002	EGFR inhibitor	Preclinical	From PubMed: PubMed 29377179 PubMed 24928736 CLUE.IO	CHEMBL1229592 PubChem??WZ-4002??
WZ8040	EGFR inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL1643989 PubChem??WZ8040??
XL647	EGFR inhibitor, VEGFR inhibitor	Phase 3	From PubMed: PubMed 30030583 PubMed 22011666 PubMed 22722787 CLUE.IO ClinicalTrials	CHEMBL3544983 PubChem??XL647?? DB11973
ZM-306416	Abl kinase inhibitor, SRC inhibitor, VEGFR inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL150315 PubChem??ZM-306416??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P00533}

Subcellular Locations ^{Source UniProt P00533}

Biological Processes ^{Source UniProt P00533}

KEGG hsa:1956 ^{Source UniProt P00533}

Reactome Pathways ^{Source UniProt P00533}

R-HSA-1227986, Signaling by ERBB2
R-HSA-1236382, Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
R-HSA-1236394, Signaling by ERBB4
R-HSA-1250196, SHC1 events in ERBB2 signaling
R-HSA-1251932, PLCG1 events in ERBB2 signaling
R-HSA-1257604, PIP3 activates AKT signaling
R-HSA-177929, Signaling by EGFR
R-HSA-179812, GRB2 events in EGFR signaling
R-HSA-180292, GAB1 signalosome
R-HSA-180336, SHC1 events in EGFR signaling
R-HSA-182971, EGFR downregulation
R-HSA-1963640, GRB2 events in ERBB2 signaling
R-HSA-1963642, PI3K events in ERBB2 signaling
R-HSA-212718, EGFR interacts with phospholipase C-gamma
R-HSA-2179392, EGFR Transactivation by Gastrin
R-HSA-2219530, Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-445144, Signal transduction by L1
R-HSA-5637810, Constitutive Signaling by EGFRvIII
R-HSA-5638303, Inhibition of Signaling by Overexpressed EGFR
R-HSA-5673001, RAF/MAP kinase cascade
R-HSA-6785631, ERBB2 Regulates Cell Motility
R-HSA-6811558, PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-8847993, ERBB2 Activates PTK6 Signaling
R-HSA-8856825, Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828, Clathrin-mediated endocytosis
R-HSA-8857538, PTK6 promotes HIF1A stabilization
R-HSA-8863795, Downregulation of ERBB2 signaling
R-HSA-8866910, TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
R-HSA-9009391, Extra-nuclear estrogen signaling
R-HSA-9013507, NOTCH3 Activation and Transmission of Signal to the Nucleus
R-HSA-9609690, HCMV Early Events
R-HSA-9634638, Estrogen-dependent nuclear events downstream of ESR-membrane signaling
R-HSA-9664565, Signaling by ERBB2 KD Mutants
R-HSA-9665348, Signaling by ERBB2 ECD mutants
R-HSA-9665686, Signaling by ERBB2 TMD/JMD mutants

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
AZD8931	EGFR inhibitor	Phase 2	From PubMed: PubMed 27654971 PubMed 24875132 PubMed 23589215 CLUE.IO ClinicalTrials	CHEMBL2408045 PubChem: 11488320 DB12183
BMS-599626	EGFR inhibitor, protein tyrosine kinase inhibitor	Phase 1	From PubMed: PubMed 21576284 PubMed 15857287 CLUE.IO ClinicalTrials	CHEMBL1645462 PubChem: 10437018 DB12318
vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	Launched	From PubMed: PubMed 29999926 PubMed 31643498 PubMed 25031937 FDA Labels: CAPRELSA From EMA: Caprelsa (PDF) CLUE.IO FDA Orange Book: vandetanib	CHEMBL24828 PubChem??vandetanib?? DB05294
WAY-200070	estrogen receptor agonist	Preclinical	From PubMed: PubMed 17824176 CLUE.IO	CHEMBL188528 PubChem??WAY-200070??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P21860}

Subcellular Locations ^{Source UniProt P21860}

Biological Processes ^{Source UniProt P21860}

KEGG hsa:2065 ^{Source UniProt P21860}

Reactome Pathways ^{Source UniProt P21860}

R-HSA-1227986, Signaling by ERBB2
R-HSA-1236394, Signaling by ERBB4
R-HSA-1250196, SHC1 events in ERBB2 signaling
R-HSA-1257604, PIP3 activates AKT signaling
R-HSA-1306955, GRB7 events in ERBB2 signaling
R-HSA-1358803, Downregulation of ERBB2:ERBB3 signaling
R-HSA-1963642, PI3K events in ERBB2 signaling
R-HSA-2219530, Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-5673001, RAF/MAP kinase cascade
R-HSA-6785631, ERBB2 Regulates Cell Motility
R-HSA-6811558, PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-8847993, ERBB2 Activates PTK6 Signaling
R-HSA-8863795, Downregulation of ERBB2 signaling
R-HSA-9664565, Signaling by ERBB2 KD Mutants
R-HSA-9665686, Signaling by ERBB2 TMD/JMD mutants

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
BTT-3033	integrin inhibitor	Preclinical	From PubMed: No search result CLUE.IO	PubChem: 49841251
E7820	angiogenesis inhibitor	Phase 2	From PubMed: PubMed 23302941 PubMed 27039386 PubMed 21208908 CLUE.IO ClinicalTrials	PubChem: 196970 DB12505
TC-I-15	integrin inhibitor	Preclinical	From PubMed: No search result CLUE.IO	PubChem??TC-I-15??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P17301}

Subcellular Locations ^{Source UniProt P17301}

Biological Processes ^{Source UniProt P17301}

KEGG hsa:3673 ^{Source UniProt P17301}

Reactome Pathways ^{Source UniProt P17301}

R-HSA-216083, Integrin cell surface interactions
R-HSA-3000157, Laminin interactions
R-HSA-3000170, Syndecan interactions
R-HSA-3000178, ECM proteoglycans
R-HSA-447041, CHL1 interactions
R-HSA-75892, Platelet Adhesion to exposed collagen
R-HSA-8874081, MET activates PTK2 signaling

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
ATN-161	integrin antagonist	Phase 2	From PubMed: PubMed 33674185 PubMed 16705310 PubMed 21900388 CLUE.IO ClinicalTrials	PubChem: 9960285

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P08648}

Subcellular Locations ^{Source UniProt P08648}

Biological Processes ^{Source UniProt P08648}

KEGG hsa:3678 ^{Source UniProt P08648}

Reactome Pathways ^{Source UniProt P08648}

R-HSA-1566948, Elastic fibre formation
R-HSA-1566977, Fibronectin matrix formation
R-HSA-202733, Cell surface interactions at the vascular wall
R-HSA-216083, Integrin cell surface interactions
R-HSA-445144, Signal transduction by L1
R-HSA-8941332, RUNX2 regulates genes involved in cell migration

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
ATN-161	integrin antagonist	Phase 2	From PubMed: PubMed 33674185 PubMed 16705310 PubMed 21900388 CLUE.IO ClinicalTrials	PubChem: 9960285
cilengitide	integrin antagonist	Phase 3	From PubMed: PubMed 25163906 PubMed 12901235 PubMed 18616418 CLUE.IO ClinicalTrials	CHEMBL429876 PubChem: 176873 DB11890
integrin-antagonist-1	integrin antagonist	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	PubChem??integrin-antagonist-1??
iRGD-peptide	integrin signaling activator	Preclinical	From PubMed: PubMed 29564914 PubMed 28815721 PubMed 28393694 CLUE.IO	PubChem??iRGD-peptide??
SB-683698	integrin antagonist	Phase 1	From PubMed: No search result CLUE.IO PubMed	CHEMBL91485 PubChem??SB-683698??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P06756}

Subcellular Locations ^{Source UniProt P06756}

Biological Processes ^{Source UniProt P06756}

KEGG hsa:3685 ^{Source UniProt P06756}

Reactome Pathways ^{Source UniProt P06756}

R-HSA-1236973, Cross-presentation of particulate exogenous antigens (phagosomes)
R-HSA-1566948, Elastic fibre formation
R-HSA-210990, PECAM1 interactions
R-HSA-2129379, Molecules associated with elastic fibres
R-HSA-216083, Integrin cell surface interactions
R-HSA-3000157, Laminin interactions
R-HSA-3000170, Syndecan interactions
R-HSA-3000178, ECM proteoglycans
R-HSA-4420097, VEGFA-VEGFR2 Pathway
R-HSA-445144, Signal transduction by L1
R-HSA-6798695, Neutrophil degranulation

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
ATN-161	integrin antagonist	Phase 2	From PubMed: PubMed 33674185 PubMed 16705310 PubMed 21900388 CLUE.IO ClinicalTrials	PubChem: 9960285
cilengitide	integrin antagonist	Phase 3	From PubMed: PubMed 25163906 PubMed 12901235 PubMed 18616418 CLUE.IO ClinicalTrials	CHEMBL429876 PubChem: 176873 DB11890

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P18084}

Subcellular Locations ^{Source UniProt P18084}

Biological Processes ^{Source UniProt P18084}

KEGG hsa:3693 ^{Source UniProt P18084}

Reactome Pathways ^{Source UniProt P18084}

R-HSA-1236973, Cross-presentation of particulate exogenous antigens (phagosomes)
R-HSA-2129379, Molecules associated with elastic fibres
R-HSA-216083, Integrin cell surface interactions
R-HSA-3000170, Syndecan interactions
R-HSA-3000178, ECM proteoglycans
R-HSA-445355, Smooth Muscle Contraction

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
GSK-J1	histone demethylase inhibitor	Preclinical	From PubMed: PubMed 30550955 CLUE.IO	CHEMBL3188597 PubChem: 56963315
GSK-J4	histone lysine demethylase inhibitor	Preclinical	From PubMed: PubMed 31545292 CLUE.IO	CHEMBL3183531 PubChem: 71729975
TC-E-5002	histone demethylase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL2424812 PubChem??TC-E-5002??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt O15550}

Subcellular Locations ^{Source UniProt O15550}

Biological Processes ^{Source UniProt O15550}

KEGG hsa:7403 ^{Source UniProt O15550}

Reactome Pathways ^{Source UniProt O15550}

R-HSA-3214842, HDMs demethylate histones
R-HSA-5617472, Activation of anterior HOX genes in hindbrain development during early embryogenesis

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
AMG-510	K-Ras inhibitor	Phase 1/Phase 2	From PubMed: PubMed 31666701 PubMed 34675734 PubMed 32955176 CLUE.IO ClinicalTrials	PubChem: 137278711 DB15569
deltarasin	phosphodiesterase inhibitor	Preclinical	From PubMed: PubMed 30366101 PubMed 25034105 CLUE.IO	CHEMBL3286929 PubChem: 73292904
K-Ras(G12C)-inhibitor-12	K-Ras inhibitor	Preclinical	From PubMed: No search result CLUE.IO	PubChem??K-Ras(G12C)-inhibitor-12??
lonafarnib	farnesyltransferase inhibitor	Phase 3	From PubMed: PubMed 33560735 PubMed 33590450 PubMed 22620979 FDA Labels: Zokinvy From EMA: Zokinvy (PDF) CLUE.IO ClinicalTrials	CHEMBL298734 PubChem??lonafarnib?? DB06448

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt G3V5T7}

Subcellular Locations ^{Source UniProt G3V5T7}

membrane

Biological Processes ^{Source UniProt G3V5T7}

signal transduction

KEGG ^{Source UniProt G3V5T7}

Reactome Pathways ^{Source UniProt G3V5T7}

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
cyclophosphamide	DNA alkylating agent	Launched	From PubMed: PubMed 19786984 PubMed 16231966 PubMed 29297205 FDA Labels: Cyclophosphamide CLUE.IO FDA Orange Book: cyclophosphamide	CHEMBL88 PubChem: 9554282
KM-0118	anticancer agent	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL221186 PubChem??KM-0118?? DB13123

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P09382}

Subcellular Locations ^{Source UniProt P09382}

Biological Processes ^{Source UniProt P09382}

KEGG hsa:3956 ^{Source UniProt P09382}

Reactome Pathways ^{Source UniProt P09382}

R-HSA-381426, Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
R-HSA-8957275, Post-translational protein phosphorylation

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
AMG-232	MDM inhibitor	Phase 2	From PubMed: PubMed 32651541 PubMed 31359240 PubMed 24967612 CLUE.IO ClinicalTrials	CHEMBL3125702 PubChem: 58573469 DB15299
CGM097	MDM inhibitor	Phase 1	From PubMed: PubMed 32651541 PubMed 34140638 PubMed 32874827 CLUE.IO ClinicalTrials	CHEMBL3601398 PubChem:
idasanutlin	MDM inhibitor	Phase 3	From PubMed: PubMed 31167802 PubMed 32651541 PubMed 32034662 CLUE.IO ClinicalTrials	CHEMBL2402737 PubChem??idasanutlin?? DB12325
JNJ-26481585	HDAC inhibitor	Phase 2	From PubMed: PubMed 23741066 PubMed 33931947 PubMed 25694345 CLUE.IO ClinicalTrials	CHEMBL2105763 PubChem??JNJ-26481585?? DB12985
lithocholic-acid	FXR antagonist, vitamin D receptor agonist	Preclinical	From PubMed: PubMed 27003186 PubMed 26579439 PubMed 15554243 CLUE.IO	CHEMBL1478 PubChem??lithocholic-acid??
milademetan	MDM inhibitor	Phase 1	From PubMed: PubMed 32651541 PubMed 33686772 PubMed 34993933 CLUE.IO ClinicalTrials	PubChem??milademetan?? DB15257
nutlin-3	MDM inhibitor	Preclinical	From PubMed: PubMed 28714398 PubMed 21391907 PubMed 23627936 CLUE.IO	CHEMBL191334 PubChem??nutlin-3??
RG7112	MDM inhibitor	Phase 1	From PubMed: PubMed 32651541 PubMed 28270530 PubMed 26459177 CLUE.IO ClinicalTrials	CHEMBL2386346 PubChem??RG7112?? DB14793
RITA	MDM inhibitor	Preclinical	From PubMed: PubMed 30995499 PubMed 31159345 PubMed 28446889 From EMA: Viekirax (PDF) CLUE.IO	CHEMBL1555354 PubChem??RITA??
SAR405838	MDM inhibitor	Phase 1	From PubMed: PubMed 28270530 PubMed 28324749 PubMed 27576846 CLUE.IO ClinicalTrials	CHEMBL2381408 PubChem??SAR405838?? DB12541
serdemetan	MDM inhibitor	Phase 1	From PubMed: PubMed 21831953 PubMed 21391905 PubMed 21504625 CLUE.IO ClinicalTrials	CHEMBL2137530 PubChem??serdemetan?? DB12027
siremadlin	MDM inhibitor	Preclinical	From PubMed: PubMed 32651541 PubMed 34921024 PubMed 34862243 CLUE.IO	CHEMBL3653256 PubChem??siremadlin??
SP-141	ubiquitin ligase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	PubChem??SP-141??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt Q00987}

Subcellular Locations ^{Source UniProt Q00987}

Biological Processes ^{Source UniProt Q00987}

KEGG hsa:4193 ^{Source UniProt Q00987}

Reactome Pathways ^{Source UniProt Q00987}

R-HSA-198323, AKT phosphorylates targets in the cytosol
R-HSA-2559580, Oxidative Stress Induced Senescence
R-HSA-2559585, Oncogene Induced Senescence
R-HSA-3232118, SUMOylation of transcription factors
R-HSA-3232142, SUMOylation of ubiquitinylation proteins
R-HSA-399719, Trafficking of AMPA receptors
R-HSA-5674400, Constitutive Signaling by AKT1 E17K in Cancer
R-HSA-5689880, Ub-specific processing proteases
R-HSA-6804756, Regulation of TP53 Activity through Phosphorylation
R-HSA-6804757, Regulation of TP53 Degradation
R-HSA-6804760, Regulation of TP53 Activity through Methylation
R-HSA-69541, Stabilization of p53
R-HSA-8941858, Regulation of RUNX3 expression and activity

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
3-amino-benzamide	PARP inhibitor	Phase 2	From PubMed: PubMed 3923344 CLUE.IO ClinicalTrials	CHEMBL81977 PubChem: 1645
4-HQN	PARP inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL266540 PubChem: 135408753
AG-14361	PARP inhibitor	Preclinical	From PubMed: PubMed 15506935 CLUE.IO	CHEMBL65892 PubChem: 9840076
BGP-15	PARP inhibitor	Phase 2	From PubMed: PubMed 31968693 PubMed 20849938 PubMed 19214941 CLUE.IO ClinicalTrials	PubChem: 92211270
BYK-204165	PARP inhibitor	Preclinical	From PubMed: No search result CLUE.IO	PubChem: 25113764
DR-2313	PARP inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL483348 PubChem: 135522417 DB07677
E7449	PARP inhibitor	Phase 2	From PubMed: PubMed 32523090 CLUE.IO ClinicalTrials	CHEMBL3644587 PubChem: 135565981
EB-47	PARP inhibitor	Preclinical	From PubMed: PubMed 26740683 CLUE.IO	PubChem: 53229989
FK-866	niacinamide phosphoribosyltransferase inhibitor	Phase 2	From PubMed: PubMed 20647743 PubMed 29752600 PubMed 17465726 CLUE.IO ClinicalTrials	CHEMBL566757 PubChem: 6914657 DB12731
iniparib	PARP inhibitor	Phase 3	From PubMed: PubMed 25349301 PubMed 23394483 PubMed 24129347 CLUE.IO ClinicalTrials	CHEMBL1170047 PubChem??iniparib?? DB13877
inosine	neurotrophic agent	Launched	From PubMed: PubMed 33921764 PubMed 31168764 PubMed 34519802 FDA Labels: Rejuvesol CLUE.IO drugs.com	CHEMBL1556 PubChem??inosine?? DB04335
ME0328	PARP inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL3092536 PubChem??ME0328??
minocycline	bacterial 30S ribosomal subunit inhibitor	Launched	From PubMed: PubMed 33568043 PubMed 23441623 PubMed 22895927 FDA Labels: CLUE.IO FDA Orange Book: minocycline hydrochloride	PubChem??minocycline?? DB117
nicotinamide	protein synthesis stimulant	Launched	From PubMed: PubMed 28220628 PubMed 32486488 PubMed 28052374 CLUE.IO drugs.com	CHEMBL1140 PubChem??nicotinamide?? DB02701
niraparib	PARP inhibitor	Launched	From PubMed: PubMed 31562799 PubMed 27717299 PubMed 29999965 FDA Labels: ZEJULA From EMA: Zejula (PDF) CLUE.IO DailyMed	CHEMBL1094636 PubChem??niraparib?? DB11793
NU-1025	PARP inhibitor	Preclinical	From PubMed: PubMed 16697054 PubMed 16154385 PubMed 29530602 CLUE.IO	CHEMBL123904 PubChem??NU-1025?? DB02690
olaparib	PARP inhibitor	Launched	From PubMed: PubMed 31157963 PubMed 32955174 PubMed 32343890 FDA Labels: Lynparza From EMA: Lynparza (PDF) CLUE.IO FDA Orange Book: olaparib	CHEMBL521686 PubChem??olaparib?? DB09074
pamiparib	PARP inhibitor	Phase 3	From PubMed: PubMed 34287805 PubMed 33772633 PubMed 33128299 CLUE.IO ClinicalTrials	CHEMBL4112930 PubChem??pamiparib?? DB14769
PJ-34	PARP inhibitor	Preclinical	From PubMed: PubMed 27102297 PubMed 25515519 PubMed 16154385 CLUE.IO	CHEMBL372303 PubChem??PJ-34?? DB08348
rucaparib	PARP inhibitor	Phase 3	From PubMed: PubMed 29999967 PubMed 31644076 PubMed 30830551 FDA Labels: Rubraca From EMA: Rubraca (PDF) CLUE.IO ClinicalTrials	CHEMBL1173055 PubChem??rucaparib?? DB12332
S-111	PARP inhibitor	Phase 2	From PubMed: PubMed 25841598 PubMed 34548132 PubMed 24738101 CLUE.IO Cortellis	CHEMBL375563 PubChem??S-111??
talazoparib	PARP inhibitor	Launched	From PubMed: PubMed 30110579 PubMed 31643933 PubMed 30601621 FDA Labels: Talzenna From EMA: Talzenna (PDF) CLUE.IO DailyMed	CHEMBL3137320 PubChem??talazoparib?? DB11760
veliparib	PARP inhibitor	Phase 3	From PubMed: PubMed 31562800 PubMed 32861273 PubMed 29501363 CLUE.IO ClinicalTrials	CHEMBL506871 PubChem??veliparib?? DB07232

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P09874}

Subcellular Locations ^{Source UniProt P09874}

Biological Processes ^{Source UniProt P09874}

KEGG hsa:142 ^{Source UniProt P09874}

Reactome Pathways ^{Source UniProt P09874}

R-HSA-110362, POLB-Dependent Long Patch Base Excision Repair
R-HSA-192814, vRNA Synthesis
R-HSA-2173795, Downregulation of SMAD2/3:SMAD4 transcriptional activity
R-HSA-3108214, SUMOylation of DNA damage response and repair proteins
R-HSA-5685939, HDR through MMEJ (alt-NHEJ)
R-HSA-5696394, DNA Damage Recognition in GG-NER
R-HSA-5696395, Formation of Incision Complex in GG-NER
R-HSA-5696400, Dual Incision in GG-NER

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
menadione	mitochondrial DNA polymerase inhibitor, phosphatase inhibitor	Launched	From PubMed: PubMed 23668406 PubMed 31644195 PubMed 35529893 FDA Labels: Menadione Phenolic CLUE.IO FDA Orange Book: menadione	CHEMBL590 PubChem??menadione?? DB00170
mitapivat	pyruvate kinase isozyme activator	Preclinical	From PubMed: PubMed 34987744 PubMed 31483964 PubMed 35417638 From EMA: Pyrukynd (PDF) CLUE.IO	PubChem??mitapivat??
TEPP-46	pyruvate kinase isozyme activator	Preclinical	From PubMed: PubMed 34240083 PubMed 32340764 PubMed 22579722 CLUE.IO	CHEMBL185588 PubChem??TEPP-46??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P14618}

Subcellular Locations ^{Source UniProt P14618}

Biological Processes ^{Source UniProt P14618}

KEGG hsa:5315 ^{Source UniProt P14618}

Reactome Pathways ^{Source UniProt P14618}

R-HSA-6798695, Neutrophil degranulation
R-HSA-70171, Glycolysis

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
amiloride	sodium channel blocker	Launched	From PubMed: PubMed 33234024 PubMed 32099995 PubMed 33047257 FDA Labels: GUNA-DIUR amiloride hydrochloride Amiloride Hydrochloride and Hydrochlorothiazide CLUE.IO FDA Orange Book: amiloride hydrochloride	CHEMBL945 PubChem: 16231 DB00594
BC-11	urokinase inhibitor	Preclinical	From PubMed: PubMed 32602793 PubMed 26578779 CLUE.IO	PubChem: 60126757
mexiletine	sodium channel blocker	Launched	From PubMed: PubMed 30000089 PubMed 31643962 PubMed 33046619 FDA Labels: From EMA: Namuscla (PDF) CLUE.IO FDA Orange Book: mexiletine hydrochloride	CHEMBL147507 PubChem??mexiletine?? DB07129
uki-1	urokinase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL107955 PubChem??uki-1??
upamostat	serine protease inhibitor	Phase 2	From PubMed: PubMed 23412098 PubMed 23579210 CLUE.IO ClinicalTrials	PubChem??upamostat?? DB13052

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P00749}

serine-type endopeptidase activity

Subcellular Locations ^{Source UniProt P00749}

Biological Processes ^{Source UniProt P00749}

KEGG hsa:5328 ^{Source UniProt P00749}

Reactome Pathways ^{Source UniProt P00749}

R-HSA-6798695, Neutrophil degranulation
R-HSA-75205, Dissolution of Fibrin Clot

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
4-chlorophenylguanidine	urokinase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL41040 PubChem: 2757788

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt Q03405}

Subcellular Locations ^{Source UniProt Q03405}

Biological Processes ^{Source UniProt Q03405}

KEGG hsa:5329 ^{Source UniProt Q03405}

Reactome Pathways ^{Source UniProt Q03405}

R-HSA-162791, Attachment of GPI anchor to uPAR
R-HSA-6798695, Neutrophil degranulation
R-HSA-75205, Dissolution of Fibrin Clot

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
repotrectinib	receptor tyrosine protein kinase inhibitor	Phase 1/Phase 2	From PubMed: PubMed 31738426 PubMed 34563714 PubMed 31720561 CLUE.IO ClinicalTrials	PubChem??repotrectinib??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P04629}

Subcellular Locations ^{Source UniProt P04629}

Biological Processes ^{Source UniProt P04629}

KEGG hsa:4914 ^{Source UniProt P04629}

Reactome Pathways ^{Source UniProt P04629}

R-HSA-167021, PLC-gamma1 signalling
R-HSA-167044, Signalling to RAS
R-HSA-170968, Frs2-mediated activation
R-HSA-170984, ARMS-mediated activation
R-HSA-177504, Retrograde neurotrophin signalling
R-HSA-187024, NGF-independant TRKA activation
R-HSA-187042, TRKA activation by NGF
R-HSA-187706, Signalling to p38 via RIT and RIN
R-HSA-198203, PI3K/AKT activation
R-HSA-198745, Signalling to STAT3

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
hyaluronic-acid	NA	Launched	From PubMed: PubMed 25877441 PubMed 32708202 PubMed 25081082 CLUE.IO drugs.com	CHEMBL2110674 PubChem??hyaluronic-acid??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P13611}

Subcellular Locations ^{Source UniProt P13611}

Biological Processes ^{Source UniProt P13611}

KEGG hsa:1462 ^{Source UniProt P13611}

Reactome Pathways ^{Source UniProt P13611}

R-HSA-1971475, A tetrasaccharide linker sequence is required for GAG synthesis
R-HSA-2022870, Chondroitin sulfate biosynthesis
R-HSA-2022923, Dermatan sulfate biosynthesis
R-HSA-2024101, CS/DS degradation
R-HSA-3000178, ECM proteoglycans
R-HSA-3560783, Defective B4GALT7 causes EDS, progeroid type
R-HSA-3560801, Defective B3GAT3 causes JDSSDHD
R-HSA-3595172, Defective CHST3 causes SEDCJD
R-HSA-3595174, Defective CHST14 causes EDS, musculocontractural type
R-HSA-3595177, Defective CHSY1 causes TPBS
R-HSA-381426, Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
R-HSA-4420332, Defective B3GALT6 causes EDSP2 and SEMDJL1
R-HSA-8957275, Post-translational protein phosphorylation

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
exherin	cadherin antagonist	Phase 2	From PubMed: PubMed 15538546 PubMed 22280327 PubMed 19190075 CLUE.IO ClinicalTrials	PubChem:

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P19022}

Subcellular Locations ^{Source UniProt P19022}

Biological Processes ^{Source UniProt P19022}

KEGG hsa:1000 ^{Source UniProt P19022}

Reactome Pathways ^{Source UniProt P19022}

R-HSA-381426, Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
R-HSA-418990, Adherens junctions interactions
R-HSA-525793, Myogenesis
R-HSA-8957275, Post-translational protein phosphorylation

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
desidustat	hypoxia inducible factor prolyl hydroxylase inhibitor	Preclinical	From PubMed: PubMed 32561478 PubMed 29712435 PubMed 33615523 CLUE.IO	PubChem: 75593290
FG-2216	hypoxia inducible factor prolyl hydroxylase inhibitor	Phase 2	From PubMed: PubMed 22362605 PubMed 21115615 CLUE.IO ClinicalTrials	CHEMBL426560 PubChem: 6914666 DB08687
FG-4592	hypoxia inducible factor prolyl hydroxylase inhibitor	Phase 3	From PubMed: PubMed 26494833 PubMed 26846333 PubMed 32171893 CLUE.IO ClinicalTrials	CHEMBL2338329 PubChem: 11256664 DB04847
MK-8617	hypoxia inducible factor prolyl hydroxylase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	PubChem??MK-8617??
molidustat	hypoxia inducible factor inhibitor	Phase 3	From PubMed: PubMed 30559105 PubMed 34569482 PubMed 33506635 CLUE.IO ClinicalTrials	CHEMBL3646118 PubChem??molidustat??
vadadustat	hypoxia inducible factor prolyl hydroxylase inhibitor	Phase 3	From PubMed: PubMed 33913637 PubMed 33913638 PubMed 32852744 CLUE.IO ClinicalTrials	CHEMBL3646221 PubChem??vadadustat?? DB12255

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt Q96KS0}

Subcellular Locations ^{Source UniProt Q96KS0}

Biological Processes ^{Source UniProt Q96KS0}

KEGG hsa:112398 ^{Source UniProt Q96KS0}

Reactome Pathways ^{Source UniProt Q96KS0}

R-HSA-1234176, Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	Launched	From PubMed: PubMed 28074653 PubMed 24794906 PubMed 17999464 FDA Labels: Immune Support CLUE.IO ClinicalTrials	CHEMBL14 PubChem: 6971205
docetaxel	tubulin polymerization inhibitor	Launched	From PubMed: PubMed 30982686 PubMed 30933324 PubMed 31560068 FDA Labels: Docetaxel Docetaxel From EMA: Docetaxel Zentiva (previously Docetaxel Winthrop) (PDF) CLUE.IO FDA Orange Book: docetaxel	CHEMBL92 PubChem: 148124 DB01248
leucomethylene-blue	nitric oxide production inhibitor, tau aggregation inhibitor	Phase 3	From PubMed: PubMed 6161670 PubMed 34399199 PubMed 20463399 CLUE.IO Unexpected Source	CHEMBL549963 PubChem??leucomethylene-blue??
methylene-blue	guanylyl cyclase inhibitor, nitric oxide production inhibitor	Launched	From PubMed: PubMed 34463662 PubMed 12845393 PubMed 31144270 CLUE.IO ClinicalTrials	CHEMBL191083 PubChem??methylene-blue?? DB08167
paclitaxel	tubulin polymerization inhibitor	Launched	From PubMed: PubMed 31223315 PubMed 23770008 PubMed 26244011 FDA Labels: Paclitaxel From EMA: Apealea (PDF) CLUE.IO FDA Orange Book: paclitaxel	CHEMBL428647 PubChem??paclitaxel?? DB01229

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P10636}

Subcellular Locations ^{Source UniProt P10636}

Biological Processes ^{Source UniProt P10636}

KEGG hsa:4137 ^{Source UniProt P10636}

Reactome Pathways ^{Source UniProt P10636}

R-HSA-264870, Caspase-mediated cleavage of cytoskeletal proteins
R-HSA-9619483, Activation of AMPK downstream of NMDARs

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
FRAX486	serine/threonine kinase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL3609326 PubChem: 68060125

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt O75914}

Subcellular Locations ^{Source UniProt O75914}

Biological Processes ^{Source UniProt O75914}

KEGG hsa:5063 ^{Source UniProt O75914}

Reactome Pathways ^{Source UniProt O75914}

R-HSA-202433, Generation of second messenger molecules
R-HSA-389359, CD28 dependent Vav1 pathway
R-HSA-3928664, Ephrin signaling
R-HSA-399954, Sema3A PAK dependent Axon repulsion
R-HSA-428540, Activation of RAC1
R-HSA-5218920, VEGFR2 mediated vascular permeability
R-HSA-5621575, CD209 (DC-SIGN) signaling
R-HSA-5627123, RHO GTPases activate PAKs
R-HSA-5687128, MAPK6/MAPK4 signaling
R-HSA-9013148, CDC42 GTPase cycle
R-HSA-9013149, RAC1 GTPase cycle
R-HSA-9013409, RHOJ GTPase cycle
R-HSA-9013420, RHOU GTPase cycle

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
GSK690693	AKT inhibitor	Phase 1	From PubMed: PubMed 21620960 PubMed 27582428 CLUE.IO ClinicalTrials	CHEMBL494089 PubChem: 16725726 DB12745

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt Q9P286}

Subcellular Locations ^{Source UniProt Q9P286}

Biological Processes ^{Source UniProt Q9P286}

KEGG hsa:57144 ^{Source UniProt Q9P286}

Reactome Pathways ^{Source UniProt Q9P286}

R-HSA-428540, Activation of RAC1
R-HSA-9013148, CDC42 GTPase cycle
R-HSA-9013149, RAC1 GTPase cycle
R-HSA-9013405, RHOD GTPase cycle
R-HSA-9013407, RHOH GTPase cycle

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
AL-8697	p38 MAPK inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL2087742 PubChem: 25060093
amuvatinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor	Phase 2	From PubMed: PubMed 22349808 PubMed 24849582 PubMed 23178951 CLUE.IO ClinicalTrials	CHEMBL2103851 PubChem: 11282283 DB12742
apatinib	RET tyrosine kinase inhibitor	Phase 3	From PubMed: PubMed 30755403 PubMed 33087333 PubMed 29663291 FDA Labels: Lapatinib From EMA: Tyverb (PDF) CLUE.IO ClinicalTrials	CHEMBL3186534 PubChem: 11315474 DB14765
cabozantinib	RET tyrosine kinase inhibitor, VEGFR inhibitor	Launched	From PubMed: PubMed 33657295 PubMed 29972759 PubMed 34029957 From EMA: Cabometyx (PDF) CLUE.IO FDA Orange Book: cabozantinib s-malate	CHEMBL2105717 PubChem: 25102847 DB08875
danusertib	Aurora kinase inhibitor, growth factor receptor inhibitor	Phase 2	From PubMed: PubMed 22242557 PubMed 20072840 PubMed 29925402 CLUE.IO ClinicalTrials	CHEMBL402548 PubChem: 11442891 DB11778
fedratinib	FLT3 inhibitor, JAK inhibitor	Launched	From PubMed: PubMed 32816422 PubMed 34633785 PubMed 32647323 FDA Labels: Inrebic From EMA: Inrebic (PDF) CLUE.IO ClinicalTrials	CHEMBL1287853 PubChem: 16722836 DB12500
GSK3179106	RET tyrosine kinase inhibitor	Phase 1	From PubMed: PubMed 30277655 CLUE.IO ClinicalTrials	CHEMBL3355009 PubChem: 78427026
imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	Launched	From PubMed: PubMed 29076384 PubMed 16122278 PubMed 30504305 FDA Labels: IMATINIB MESYLATE IMATINIB MESYLATE IMATINIB MESYLATE From EMA: Imatinib Accord (PDF) CLUE.IO FDA Orange Book: imatinib mesylate	CHEMBL941 PubChem??imatinib?? DB00619
lenvatinib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	Launched	From PubMed: PubMed 30993651 PubMed 32659252 PubMed 25671254 From EMA: Kisplyx (PDF) CLUE.IO FDA Orange Book: lenvatinib mesylate	CHEMBL1289601 PubChem??lenvatinib?? DB09078
linifanib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	Phase 3	From PubMed: PubMed 20698720 PubMed 25936222 PubMed 25488963 CLUE.IO ClinicalTrials	CHEMBL223360 PubChem??linifanib??
lucitanib	FGFR inhibitor, VEGFR inhibitor	Phase 2	From PubMed: PubMed 31619444 PubMed 31770593 PubMed 30684019 CLUE.IO ClinicalTrials	CHEMBL2220486 PubChem??lucitanib?? DB11845
motesanib	KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	Phase 3	From PubMed: PubMed 21534718 PubMed 25032887 PubMed 25772756 CLUE.IO PubMed	CHEMBL572881 PubChem??motesanib?? DB05575
ON123300	CDK inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL3115681 PubChem??ON123300??
ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	Launched	From PubMed: PubMed 28969556 PubMed 31643461 PubMed 29567798 FDA Labels: Iclusig From EMA: Iclusig (PDF) CLUE.IO FDA Orange Book: ponatinib hydrochloride	CHEMBL1171837 PubChem??ponatinib?? DB08901
PP-1	SRC inhibitor	Preclinical	From PubMed: PubMed 28603940 PubMed 24840916 PubMed 33706930 CLUE.IO	CHEMBL306380 PubChem??PP-1?? DB01809
quizartinib	FLT3 inhibitor	Phase 3	From PubMed: PubMed 31114157 PubMed 32772726 PubMed 30997851 From EMA: Vanflyta (PDF) CLUE.IO ClinicalTrials	CHEMBL576982 PubChem??quizartinib?? DB12874
R406	SYK inhibitor	Phase 1	From PubMed: PubMed 16946104 PubMed 26739683 PubMed 26519231 CLUE.IO Unexpected Source	CHEMBL475251 PubChem??R406?? DB07159
regorafenib	FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	Launched	From PubMed: PubMed 30069758 PubMed 27932229 PubMed 23177514 FDA Labels: Stivarga From EMA: Stivarga (PDF) CLUE.IO FDA Orange Book: regorafenib	CHEMBL1946170 PubChem??regorafenib?? DB08896
semaxanib	VEGFR inhibitor	Phase 3	From PubMed: PubMed 16736151 PubMed 31691360 PubMed 16449240 CLUE.IO ClinicalTrials	CHEMBL276711 PubChem??semaxanib?? DB06436
sitravatinib	receptor tyrosine protein kinase inhibitor	Phase 3	From PubMed: PubMed 35442707 PubMed 33356674 CLUE.IO ClinicalTrials	CHEMBL3989926 PubChem??sitravatinib?? DB15036
sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	Launched	From PubMed: PubMed 32532960 PubMed 31918403 PubMed 30575484 FDA Labels: Nexavar Sorafenib Tosylate From EMA: Nexavar (PDF) CLUE.IO FDA Orange Book: sorafenib tosylate	CHEMBL1336 PubChem??sorafenib?? DB00398
SPP86	receptor tyrosine protein kinase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL2058538 PubChem??SPP86??
sunitinib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	Launched	From PubMed: PubMed 30779529 PubMed 33657295 PubMed 33284113 FDA Labels: Sunitinib malate From EMA: Sunitinib Accord (PDF) CLUE.IO FDA Orange Book: sunitinib malate	CHEMBL535 PubChem??sunitinib?? DB01268
vandetanib	EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	Launched	From PubMed: PubMed 29999926 PubMed 31643498 PubMed 25031937 FDA Labels: CAPRELSA From EMA: Caprelsa (PDF) CLUE.IO FDA Orange Book: vandetanib	CHEMBL24828 PubChem??vandetanib?? DB05294

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P07949}

Subcellular Locations ^{Source UniProt P07949}

Biological Processes ^{Source UniProt P07949}

KEGG hsa:5979 ^{Source UniProt P07949}

Reactome Pathways ^{Source UniProt P07949}

R-HSA-5673001, RAF/MAP kinase cascade
R-HSA-8853659, RET signaling

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
cabazitaxel	microtubule inhibitor	Launched	From PubMed: PubMed 31643851 PubMed 33581798 PubMed 31566937 From EMA: Cabazitaxel Accord (PDF) CLUE.IO FDA Orange Book: cabazitaxel	CHEMBL1201748 PubChem: 9854073 DB06772
colchicine	microtubule inhibitor	Launched	From PubMed: PubMed 32865380 PubMed 29336252 PubMed 33961006 FDA Labels: Colchicine Probenecid and Colchicine CLUE.IO FDA Orange Book: colchicine	CHEMBL107 PubChem: 6167 DB1394
docetaxel	tubulin polymerization inhibitor	Launched	From PubMed: PubMed 30982686 PubMed 30933324 PubMed 31560068 FDA Labels: Docetaxel Docetaxel From EMA: Docetaxel Zentiva (previously Docetaxel Winthrop) (PDF) CLUE.IO FDA Orange Book: docetaxel	CHEMBL92 PubChem: 148124 DB01248
paclitaxel	tubulin polymerization inhibitor	Launched	From PubMed: PubMed 31223315 PubMed 23770008 PubMed 26244011 FDA Labels: Paclitaxel From EMA: Apealea (PDF) CLUE.IO FDA Orange Book: paclitaxel	CHEMBL428647 PubChem??paclitaxel?? DB01229
vinorelbine	tubulin polymerization inhibitor	Launched	From PubMed: PubMed 33332190 PubMed 34170745 PubMed 32407216 FDA Labels: Vinorelbine CLUE.IO FDA Orange Book: vinorelbine, vinorelbine tartrate	CHEMBL553025 PubChem??vinorelbine?? DB00361

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt Q13509}

Subcellular Locations ^{Source UniProt Q13509}

Biological Processes ^{Source UniProt Q13509}

KEGG hsa:10381 ^{Source UniProt Q13509}

Reactome Pathways ^{Source UniProt Q13509}

R-HSA-1445148, Translocation of SLC2A4 (GLUT4) to the plasma membrane
R-HSA-190840, Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane
R-HSA-190861, Gap junction assembly
R-HSA-2132295, MHC class II antigen presentation
R-HSA-2467813, Separation of Sister Chromatids
R-HSA-2500257, Resolution of Sister Chromatid Cohesion
R-HSA-3371497, HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
R-HSA-380320, Recruitment of NuMA to mitotic centrosomes
R-HSA-389957, Prefoldin mediated transfer of substrate to CCT/TriC
R-HSA-389960, Formation of tubulin folding intermediates by CCT/TriC
R-HSA-389977, Post-chaperonin tubulin folding pathway
R-HSA-437239, Recycling pathway of L1
R-HSA-5610787, Hedgehog 'off' state
R-HSA-5617833, Cilium Assembly
R-HSA-5620924, Intraflagellar transport
R-HSA-5626467, RHO GTPases activate IQGAPs
R-HSA-5663220, RHO GTPases Activate Formins
R-HSA-6807878, COPI-mediated anterograde transport
R-HSA-6811434, COPI-dependent Golgi-to-ER retrograde traffic
R-HSA-6811436, COPI-independent Golgi-to-ER retrograde traffic
R-HSA-68877, Mitotic Prometaphase
R-HSA-8852276, The role of GTSE1 in G2/M progression after G2 checkpoint
R-HSA-8955332, Carboxyterminal post-translational modifications of tubulin
R-HSA-9609690, HCMV Early Events
R-HSA-9609736, Assembly and cell surface presentation of NMDA receptors
R-HSA-9619483, Activation of AMPK downstream of NMDARs
R-HSA-9646399, Aggrephagy
R-HSA-9648025, EML4 and NUDC in mitotic spindle formation
R-HSA-9668328, Sealing of the nuclear envelope (NE) by ESCRT-III
R-HSA-983189, Kinesins

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
alda-1	aldehyde dehydrogenase activator	Preclinical	From PubMed: PubMed 22040938 PubMed 31697578 PubMed 32896553 CLUE.IO	CHEMBL465952 PubChem: 831629
coenzyme-I	NA	Phase 2	From PubMed: PubMed 29249689 PubMed 33353981 PubMed 31577933 CLUE.IO Integrity	PubChem: 439153 DB00157
CVT-10216	aldehyde dehydrogenase inhibitor	Phase 1	From PubMed: PubMed 22574676 CLUE.IO guidebook	PubChem: 23661666
daidzin	antioxidant	Phase 1	From PubMed: PubMed 30818043 PubMed 25594250 PubMed 11187733 CLUE.IO ClinicalTrials	CHEMBL486422 PubChem: 107971 DB02115
diphenyleneiodonium	nitric oxide synthase inhibitor	Preclinical	From PubMed: PubMed 31434645 PubMed 23085520 PubMed 7003824 CLUE.IO	CHEMBL365739 PubChem:
disulfiram	aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist	Launched	From PubMed: PubMed 31643433 PubMed 31084595 PubMed 33426580 FDA Labels: Disulfiram CLUE.IO FDA Orange Book: disulfiram	CHEMBL964 PubChem: 3117 DB00822
guanidine	HSP inhibitor	Launched	From PubMed: PubMed 33640673 PubMed 31671653 PubMed 21139254 CLUE.IO FDA Orange Book: guanidine hydrochloride	CHEMBL821 PubChem: 3520 DB00536
nadide	free radical scavenger	Launched	From PubMed: PubMed 29249689 PubMed 33353981 PubMed 31577933 FDA Labels: Zeel Zeel GUNA-MATRIX CLUE.IO drugs.com	PubChem??nadide??
thioctic-acid	reducing agent	Launched	From PubMed: PubMed 31405030 PubMed 29191830 PubMed 25381809 CLUE.IO ClinicalTrials	CHEMBL1234071 PubChem??thioctic-acid?? DB166

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P05091}

Subcellular Locations ^{Source UniProt P05091}

Biological Processes ^{Source UniProt P05091}

KEGG hsa:217 ^{Source UniProt P05091}

Reactome Pathways ^{Source UniProt P05091}

R-HSA-380612, Metabolism of serotonin
R-HSA-71384, Ethanol oxidation

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
dexamethasone	glucocorticoid receptor agonist	Launched	From PubMed: PubMed 31595319 PubMed 31755076 PubMed 31416827 From EMA: Ozurdex (PDF) CLUE.IO FDA Orange Book: dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate	CHEMBL384467 PubChem: 5743 DB01234
hydrocortisone	glucocorticoid receptor agonist	Launched	From PubMed: PubMed 30441816 PubMed 26916176 PubMed 32394073 From EMA: Plenadren (PDF) CLUE.IO FDA Orange Book: hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone cypionate, hydrocortisone probutate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone valerate	CHEMBL389621 PubChem??hydrocortisone?? DB00741

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P04083}

Subcellular Locations ^{Source UniProt P04083}

Biological Processes ^{Source UniProt P04083}

KEGG hsa:301 ^{Source UniProt P04083}

Reactome Pathways ^{Source UniProt P04083}

R-HSA-416476, G alpha (q) signalling events
R-HSA-418594, G alpha (i) signalling events
R-HSA-444473, Formyl peptide receptors bind formyl peptides and many other ligands
R-HSA-445355, Smooth Muscle Contraction
R-HSA-6785807, Interleukin-4 and Interleukin-13 signaling

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
L-glutamic-acid	glutamate receptor agonist	Launched	From PubMed: PubMed 12467378 PubMed 12481981 PubMed 2900349 CLUE.IO FDA	CHEMBL575060 PubChem??L-glutamic-acid?? DB00142
L-leucine	NA	Phase 3	From PubMed: PubMed 25552397 PubMed 31055970 PubMed 33741748 CLUE.IO ClinicalTrials	CHEMBL291962 PubChem??L-leucine?? DB00149
MC-1	NA	Phase 3	From PubMed: PubMed 16255681 PubMed 20641698 PubMed 20641555 CLUE.IO ClinicalTrials	CHEMBL82202 PubChem??MC-1?? DB00114

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P54687}

Subcellular Locations ^{Source UniProt P54687}

Biological Processes ^{Source UniProt P54687}

KEGG hsa:586 ^{Source UniProt P54687}

Reactome Pathways ^{Source UniProt P54687}

R-HSA-70895, Branched-chain amino acid catabolism

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
AT-406	IAP antagonist	Phase 1	From PubMed: PubMed 33460574 PubMed 34874182 PubMed 25716544 CLUE.IO ClinicalTrials	CHEMBL2158051 PubChem: 25022340
AZD5582	XIAP inhibitor	Preclinical	From PubMed: PubMed 33007800 CLUE.IO	CHEMBL3108827 PubChem: 49847690
birinapant	XIAP inhibitor	Phase 2	From PubMed: PubMed 26333381 PubMed 26566079 PubMed 30631429 CLUE.IO ClinicalTrials	CHEMBL3039522 PubChem: 49836020 DB11782
GDC-0152	XIAP inhibitor	Phase 1	From PubMed: PubMed 22623056 CLUE.IO ClinicalTrials	CHEMBL2063869 PubChem: 46940575 DB12380
SM-164	XIAP inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL1774154 PubChem??SM-164??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt Q13489}

Subcellular Locations ^{Source UniProt Q13489}

Biological Processes ^{Source UniProt Q13489}

KEGG hsa:330 ^{Source UniProt Q13489}

Reactome Pathways ^{Source UniProt Q13489}

R-HSA-168638, NOD1/2 Signaling Pathway
R-HSA-168927, TICAM1, RIP1-mediated IKK complex recruitment
R-HSA-5213460, RIPK1-mediated regulated necrosis
R-HSA-5357905, Regulation of TNFR1 signaling
R-HSA-5357956, TNFR1-induced NFkappaB signaling pathway
R-HSA-5668541, TNFR2 non-canonical NF-kB pathway
R-HSA-5675482, Regulation of necroptotic cell death
R-HSA-5676594, TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
R-HSA-5689880, Ub-specific processing proteases
R-HSA-937041, IKK complex recruitment mediated by RIP1

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
5-fluorouracil	thymidylate synthase inhibitor	Launched	From PubMed: PubMed 12724731 PubMed 31756363 PubMed 2656050 CLUE.IO drugs.com	CHEMBL185 PubChem: 3385 DB00544
hyaluronic-acid	NA	Launched	From PubMed: PubMed 25877441 PubMed 32708202 PubMed 25081082 CLUE.IO drugs.com	CHEMBL2110674 PubChem??hyaluronic-acid??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P16070}

Subcellular Locations ^{Source UniProt P16070}

Biological Processes ^{Source UniProt P16070}

KEGG hsa:960 ^{Source UniProt P16070}

Reactome Pathways ^{Source UniProt P16070}

R-HSA-1474228, Degradation of the extracellular matrix
R-HSA-202733, Cell surface interactions at the vascular wall
R-HSA-216083, Integrin cell surface interactions
R-HSA-2160916, Hyaluronan uptake and degradation
R-HSA-6798695, Neutrophil degranulation
R-HSA-877300, Interferon gamma signaling

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
aceneuramic-acid	NA	Phase 3	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL165084 PubChem: 445063 DB04265
apoptosis-activator-II	carboxylesterase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL375126 PubChem: 1901244
avasimibe	ACAT inhibitor	Phase 3	From PubMed: PubMed 12099161 PubMed 12595916 PubMed 12498009 CLUE.IO PubMed	CHEMBL101309 PubChem: 166558 DB06442
benzoin	NA	Preclinical	From PubMed: PubMed 28809427 PubMed 27340440 PubMed 2682234 FDA Labels: Benzoin Compound Tincture Benz Protect Blistex Kank-A Benzoin CLUE.IO	CHEMBL19677 PubChem: 640038
cholic-acid	bile acid	Launched	From PubMed: PubMed 31643599 PubMed 27003186 PubMed 24199211 CLUE.IO FDA	CHEMBL205596 PubChem: 221493 DB02659
CI-976	ACAT inhibitor	Phase 1	From PubMed: PubMed 11347152 PubMed 28839257 PubMed 28017399 CLUE.IO Pharmaprojects	CHEMBL22373 PubChem: 122327
oseltamivir-phosphate	neuraminidase inhibitor	Launched	From PubMed: PubMed 31931672 PubMed 33073355 PubMed 24757915 CLUE.IO FDA Orange Book: oseltamivir phosphate	CHEMBL1229 PubChem??oseltamivir-phosphate?? DB00198
probucol	atherogenesis inhibitor	Launched	From PubMed: PubMed 17824073 PubMed 11122724 PubMed 26125504 CLUE.IO FDA Orange Book: probucol	CHEMBL608 PubChem??probucol?? DB01599

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P23141}

Subcellular Locations ^{Source UniProt P23141}

Biological Processes ^{Source UniProt P23141}

KEGG hsa:1066 ^{Source UniProt P23141}

Reactome Pathways ^{Source UniProt P23141}

R-HSA-2022377, Metabolism of Angiotensinogen to Angiotensins
R-HSA-211945, Phase I - Functionalization of compounds

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
boceprevir	HCV inhibitor	Launched	From PubMed: PubMed 29999670 PubMed 31643571 PubMed 22076489 From EMA: Victrelis (PDF) CLUE.IO FDA Orange Book: boceprevir	CHEMBL1233448 PubChem: 10324368
E-64	calpain inhibitor, cysteine protease inhibitor	Preclinical	From PubMed: PubMed 28608197 PubMed 1877091 PubMed 26100824 CLUE.IO	CHEMBL374508 PubChem: 123985
LY3000328	cathepsin inhibitor	Phase 1	From PubMed: PubMed 25039273 CLUE.IO ClinicalTrials	CHEMBL3342553 PubChem??LY3000328??
VBY-825	cathepsin inhibitor	Preclinical	From PubMed: No search result CLUE.IO	PubChem??VBY-825??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P25774}

Subcellular Locations ^{Source UniProt P25774}

Biological Processes ^{Source UniProt P25774}

KEGG hsa:1520 ^{Source UniProt P25774}

Reactome Pathways ^{Source UniProt P25774}

R-HSA-1236977, Endosomal/Vacuolar pathway
R-HSA-1474228, Degradation of the extracellular matrix
R-HSA-1679131, Trafficking and processing of endosomal TLR
R-HSA-2022090, Assembly of collagen fibrils and other multimeric structures
R-HSA-2132295, MHC class II antigen presentation
R-HSA-6798695, Neutrophil degranulation

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
AZD5069	CC chemokine receptor antagonist	Phase 2	From PubMed: PubMed 30804927 PubMed 26341987 PubMed 25681277 CLUE.IO ClinicalTrials	PubChem: 56645576
AZD8797	CC chemokine receptor antagonist	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL2349310 PubChem: 11965767
danirixin	CC chemokine receptor antagonist	Phase 2	From PubMed: PubMed 33123802 PubMed 31056840 PubMed 30804927 CLUE.IO ClinicalTrials	CHEMBL3039531 PubChem: 24780598 DB11922
indoprofen	cyclooxygenase inhibitor, prostanoid receptor antagonist	Withdrawn	From PubMed: PubMed 6998792 PubMed 373995 PubMed 340006 CLUE.IO Wikipedia	CHEMBL264931 PubChem??indoprofen??
navarixin	CC chemokine receptor antagonist	Phase 2	From PubMed: PubMed 27886903 PubMed 26154136 PubMed 28833645 CLUE.IO ClinicalTrials	CHEMBL216981 PubChem??navarixin??
reparixin	CC chemokine receptor antagonist	Phase 3	From PubMed: PubMed 17346425 PubMed 31924241 PubMed 34476645 CLUE.IO ClinicalTrials	CHEMBL191413 PubChem??reparixin?? DB12614
SB-225002	CC chemokine receptor antagonist	Preclinical	From PubMed: PubMed 10771661 CLUE.IO	CHEMBL239767 PubChem??SB-225002??
SRT3190	CC chemokine receptor antagonist	Preclinical	From PubMed: No search result CLUE.IO	PubChem??SRT3190??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P25025}

Subcellular Locations ^{Source UniProt P25025}

Biological Processes ^{Source UniProt P25025}

KEGG hsa:3579 ^{Source UniProt P25025}

Reactome Pathways ^{Source UniProt P25025}

R-HSA-380108, Chemokine receptors bind chemokines
R-HSA-418594, G alpha (i) signalling events
R-HSA-6798695, Neutrophil degranulation

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
17-hydroxyprogesterone-caproate	progesterone receptor agonist	Launched	From PubMed: PubMed 30339274 PubMed 26663620 PubMed 33487666 CLUE.IO FDA Orange Book: hydroxyprogesterone caproate	CHEMBL1200848 PubChem: 169870 DB06789
abiraterone-acetate	androgen biosynthesis inhibitor	Launched	From PubMed: PubMed 30987939 PubMed 25601341 PubMed 31727538 CLUE.IO FDA Orange Book: abiraterone acetate	CHEMBL271227 PubChem: 9821849
afimoxifene	estrogen receptor antagonist	Phase 2	From PubMed: PubMed 17351746 PubMed 29924509 PubMed 25964209 CLUE.IO ClinicalTrials	CHEMBL489 PubChem: 449459 DB04468
ambrisentan	endothelin receptor antagonist	Launched	From PubMed: PubMed 31643986 PubMed 26308684 PubMed 21623643 FDA Labels: Ambrisentan From EMA: Ambrisentan Mylan (PDF) CLUE.IO FDA Orange Book: ambrisentan	CHEMBL1111 PubChem: 6918493 DB06403
amitriptyline	norepinephrine inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin–norepinephrine reuptake inhibitor (SNRI)	Launched	From PubMed: PubMed 33438398 PubMed 27165014 PubMed 26395929 CLUE.IO FDA Orange Book: amitriptyline hydrochloride	CHEMBL629 PubChem: 2160 DB00321
apatinib	RET tyrosine kinase inhibitor	Phase 3	From PubMed: PubMed 30755403 PubMed 33087333 PubMed 29663291 FDA Labels: Lapatinib From EMA: Tyverb (PDF) CLUE.IO ClinicalTrials	CHEMBL3186534 PubChem: 11315474 DB14765
arbidol	cytochrome P450 inhibitor	Launched	From PubMed: PubMed 24769245 PubMed 33253656 PubMed 34347937 CLUE.IO drugs.com	CHEMBL1214598 PubChem: 28446253 DB13609
argatroban	thrombin inhibitor	Launched	From PubMed: PubMed 29999834 PubMed 34275554 PubMed 33774764 FDA Labels: ARGATROBAN CLUE.IO FDA Orange Book: argatroban	CHEMBL59461 PubChem: 152951 DB278
artemether	antimalarial agent	Launched	From PubMed: PubMed 25209020 PubMed 31210357 PubMed 22496476 FDA Labels: COARTEM COARTEM CLUE.IO FDA Orange Book: artemether	CHEMBL566534 PubChem: 68911 DB06697
astemizole	histamine receptor antagonist	Withdrawn	From PubMed: PubMed 21443504 PubMed 2892659 PubMed 1974137 CLUE.IO Wikipedia	CHEMBL296419 PubChem: 2247 DB00637
atorvastatin	HMGCR inhibitor	Launched	From PubMed: PubMed 28658127 PubMed 30563586 PubMed 33482034 FDA Labels: ATORVASTATIN CALCIUM ATORVASTATIN CALCIUM Amlodipine and Atorvastatin CLUE.IO FDA Orange Book: atorvastatin calcium	CHEMBL1487 PubChem: 60823 DB01076
axitinib	PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor	Launched	From PubMed: PubMed 30779529 PubMed 33284113 PubMed 30779531 FDA Labels: INLYTA INLYTA From EMA: Inlyta (PDF) CLUE.IO FDA Orange Book: axitinib	CHEMBL1289926 PubChem: 6450551 DB06626
beclomethasone-dipropionate	glucocorticoid receptor agonist	Launched	From PubMed: PubMed 26558604 PubMed 29255325 PubMed 30101623 CLUE.IO FDA Orange Book: beclomethasone dipropionate, beclomethasone dipropionate monohydrate	CHEMBL1200500 PubChem: 21700 DB00394
benidipine	calcium channel blocker	Launched	From PubMed: PubMed 30589098 PubMed 33001356 PubMed 23971692 CLUE.IO drugs.com	CHEMBL2359165 PubChem: 656667
boceprevir	HCV inhibitor	Launched	From PubMed: PubMed 29999670 PubMed 31643571 PubMed 22076489 From EMA: Victrelis (PDF) CLUE.IO FDA Orange Book: boceprevir	CHEMBL1233448 PubChem: 10324368
budesonide	glucocorticoid receptor agonist	Launched	From PubMed: PubMed 30007787 PubMed 15355126 PubMed 31451207 FDA Labels: Budesonide BREYNA BREZTRI From EMA: Jorveza (PDF) CLUE.IO FDA Orange Book: budesonide	CHEMBL137 PubChem: 63006 DB1222
cabazitaxel	microtubule inhibitor	Launched	From PubMed: PubMed 31643851 PubMed 33581798 PubMed 31566937 From EMA: Cabazitaxel Accord (PDF) CLUE.IO FDA Orange Book: cabazitaxel	CHEMBL1201748 PubChem: 9854073 DB06772
calcitriol	vitamin D receptor agonist	Launched	From PubMed: PubMed 34508882 PubMed 16886675 PubMed 15026558 FDA Labels: CLUE.IO FDA Orange Book: calcitriol	CHEMBL846 PubChem: 5280453 DB00136
cilostazol	phosphodiesterase inhibitor	Launched	From PubMed: PubMed 31260229 PubMed 33388632 PubMed 32881655 FDA Labels: Cilostazol CLUE.IO FDA Orange Book: cilostazol	CHEMBL799 PubChem: 2754 DB01166
cisapride	serotonin receptor agonist	Withdrawn	From PubMed: PubMed 21249695 PubMed 2647116 PubMed 10808885 CLUE.IO Wikipedia	CHEMBL560739 PubChem: 6917698 DB00604
clarithromycin	bacterial 50S ribosomal subunit inhibitor	Launched	From PubMed: PubMed 8851453 PubMed 31628882 PubMed 18486039 CLUE.IO FDA Orange Book: clarithromycin	CHEMBL1741 PubChem:
clopidogrel	purinergic receptor antagonist	Launched	From PubMed: PubMed 30998396 PubMed 34708996 PubMed 32284734 From EMA: DuoPlavin (PDF) CLUE.IO FDA Orange Book: clopidogrel, clopidogrel bisulfate	CHEMBL1771 PubChem: 60606 DB00758
cobicistat	cytochrome P450 inhibitor	Launched	From PubMed: PubMed 27227212 PubMed 29915897 PubMed 27189707 FDA Labels: Tybost PREZCOBIX Symtuza From EMA: Symtuza (PDF) CLUE.IO FDA Orange Book: cobicistat	CHEMBL2095208 PubChem: 25151504 DB09065
crizotinib	ALK tyrosine kinase receptor inhibitor	Launched	From PubMed: PubMed 33207094 PubMed 28586279 PubMed 30280657 FDA Labels: Xalkori From EMA: Xalkori (PDF) CLUE.IO FDA Orange Book: crizotinib	CHEMBL601719 PubChem: 11626560 DB08865
cyclophosphamide	DNA alkylating agent	Launched	From PubMed: PubMed 19786984 PubMed 16231966 PubMed 29297205 FDA Labels: Cyclophosphamide CLUE.IO FDA Orange Book: cyclophosphamide	CHEMBL88 PubChem: 9554282
cyclosporin-A	calcineurin inhibitor	Launched	From PubMed: PubMed 8513650 PubMed 21955136 PubMed 17636804 CLUE.IO FDA Orange Book: cyclosporine	CHEMBL386389 PubChem: PubChem: 5284373 DB00091
dapivirine	non-nucleoside reverse transcriptase inhibitor	Phase 3	From PubMed: PubMed 34910276 PubMed 33181534 PubMed 33632073 CLUE.IO ClinicalTrials	CHEMBL70663 PubChem: 214347 DB08639
darunavir	HIV protease inhibitor	Launched	From PubMed: PubMed 30000602 PubMed 31643326 PubMed 33461696 FDA Labels: Symtuza PREZISTA PREZCOBIX From EMA: Symtuza (PDF) CLUE.IO FDA Orange Book: darunavir ethanolate	CHEMBL1323 PubChem: 213039 DB01264
dehydroepiandrosterone	protein synthesis stimulant	Launched	From PubMed: PubMed 30029723 PubMed 25022952 PubMed 27927044 FDA Labels: Hormone Combination Hormone Harmony Professional Weight Support Weight Management Hormone Balance Professional Weight Maintenance HA2CG Evolution CLUE.IO ClinicalTrials	CHEMBL90593 PubChem: 5881 DB01708
dexamethasone	glucocorticoid receptor agonist	Launched	From PubMed: PubMed 31595319 PubMed 31755076 PubMed 31416827 From EMA: Ozurdex (PDF) CLUE.IO FDA Orange Book: dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate	CHEMBL384467 PubChem: 5743 DB01234
dextromethorphan	glutamate receptor antagonist, sigma receptor agonist	Launched	From PubMed: PubMed 30000516 PubMed 24742799 PubMed 31566163 From EMA: Nuedexta (PDF) CLUE.IO FDA Orange Book: dextromethorphan hydrobromide, dextromethorphan polistirex	CHEMBL52440 PubChem: 5360696 DB00514
diltiazem	calcium channel blocker	Launched	From PubMed: PubMed 3882198 PubMed 33774968 PubMed 34781150 FDA Labels: CLUE.IO FDA Orange Book: diltiazem hydrochloride, diltiazem malate	CHEMBL23 PubChem: 39186 DB00343
dolutegravir	HIV integrase inhibitor	Launched	From PubMed: PubMed 31643672 PubMed 31865558 PubMed 31339676 From EMA: Dovato (PDF) CLUE.IO FDA Orange Book: dolutegravir sodium	CHEMBL1229211 PubChem: 54726191 DB08930
domperidone	dopamine receptor antagonist	Launched	From PubMed: PubMed 30000430 PubMed 17488253 PubMed 28440671 CLUE.IO drugs.com	CHEMBL219916 PubChem: 3151 DB01184
dutasteride	5 alpha reductase inhibitor	Launched	From PubMed: PubMed 28294070 PubMed 29447628 PubMed 32202088 FDA Labels: AVODART Dutasteride and tamsulosin hydrochloride Dutasteride and tamsulosin hydrochloride CLUE.IO FDA Orange Book: dutasteride	CHEMBL1200969 PubChem: 6918296 DB01126
edoxaban	coagulation factor inhibitor	Launched	From PubMed: PubMed 24251359 PubMed 32865374 PubMed 34449183 FDA Labels: SAVAYSA From EMA: Roteas (PDF) CLUE.IO FDA Orange Book: edoxaban tosylate	CHEMBL1269025 PubChem: 10280735 DB09075
efavirenz	HIV protease inhibitor	Launched	From PubMed: PubMed 33155233 PubMed 31324697 PubMed 31339676 FDA Labels: Efavirenz Efavirenz, emtricitabine and tenofovir disoproxil fumarate From EMA: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (PDF) CLUE.IO FDA Orange Book: efavirenz	CHEMBL223228 PubChem: 64139 DB00625
enilconazole	sterol demethylase inhibitor	Launched	From PubMed: PubMed 23813824 PubMed 26990840 PubMed 16761984 CLUE.IO drugs.com	CHEMBL356918 PubChem: 6992070
eplerenone	cytochrome P450 inhibitor	Launched	From PubMed: PubMed 33630486 PubMed 31643265 PubMed 18404673 FDA Labels: Eplerenone CLUE.IO FDA Orange Book: eplerenone	CHEMBL1095097 PubChem: 443872 DB00700
estradiol	estrogen receptor agonist	Launched	From PubMed: PubMed 25205317 PubMed 29566418 PubMed 25159104 From EMA: Zoely (PDF) CLUE.IO FDA Orange Book: estradiol, estradiol acetate, estradiol cypionate, estradiol hemihydrate, estradiol valerate, ethinyl estradiol, polyestradiol phosphate	CHEMBL135 PubChem: 5757 DB00783
etoposide	topoisomerase inhibitor	Launched	From PubMed: PubMed 9893622 PubMed 2653712 PubMed 34202987 FDA Labels: Etoposide ETOPOPHOS CLUE.IO FDA Orange Book: etoposide, etoposide phosphate	CHEMBL44657 PubChem: 36462 DB00773
everolimus	mTOR inhibitor	Launched	From PubMed: PubMed 30069763 PubMed 29752413 PubMed 26703889 FDA Labels: Everolimus From EMA: Votubia (PDF) CLUE.IO FDA Orange Book: everolimus	PubChem: DB159
fenretinide	apoptosis stimulant, retinoid receptor agonist	Phase 3	From PubMed: PubMed 32471278 PubMed 34577553 PubMed 16850162 CLUE.IO ClinicalTrials	CHEMBL7301 PubChem: 5288209 DB05076
fluconazole	sterol demethylase inhibitor	Launched	From PubMed: PubMed 8448970 PubMed 33587857 PubMed 31688884 FDA Labels: Fluconazole Fluconazole Fluconazole CICLOPIROX 8% / FLUCONAZOLE 1% / TERBINAFINE HCL 1% FLUCONAZOLE 4% / IBUPROFEN 2% / ITRACONAZOLE 1% / TERBINAFINE HCL 4% CLUE.IO FDA Orange Book: fluconazole	CHEMBL106 PubChem: 3365 DB00196
fluticasone-propionate	glucocorticoid receptor agonist	Launched	From PubMed: PubMed 29857783 PubMed 29582249 PubMed 27579634 CLUE.IO FDA Orange Book: fluticasone propionate	CHEMBL1473 PubChem: 444036 DB00588
GDC-0068	AKT inhibitor	Phase 3	From PubMed: PubMed 32091335 PubMed 29417298 PubMed 34221179 CLUE.IO ClinicalTrials	CHEMBL2177390 PubChem: 24788740 DB11743
glycerol-phenylbutyrate	sigma receptor ligand	Phase 1	From PubMed: PubMed 29381293 PubMed 30982989 PubMed 25118801 CLUE.IO ClinicalTrials	PubChem: 10482134
granisetron	serotonin receptor antagonist	Launched	From PubMed: PubMed 19943709 PubMed 7606907 PubMed 32623521 FDA Labels: SUSTOL Granisetron Hydrochloride From EMA: Sancuso (PDF) CLUE.IO FDA Orange Book: granisetron, granisetron hydrochloride	CHEMBL1290003 PubChem: DB00889
guanfacine	adrenergic receptor agonist	Launched	From PubMed: PubMed 31643901 PubMed 30000582 PubMed 33075480 From EMA: Intuniv (PDF) CLUE.IO FDA Orange Book: guanfacine hydrochloride	CHEMBL862 PubChem: 3519 DB01018
halofantrine	antimalarial agent	Launched	From PubMed: PubMed 30000758 PubMed 8703186 PubMed 7955774 CLUE.IO FDA Orange Book: halofantrine hydrochloride	CHEMBL117 PubChem??halofantrine?? DB1218
ifosfamide	DNA alkylating agent	Launched	From PubMed: PubMed 17355105 PubMed 3286879 PubMed 1804803 FDA Labels: Ifosfamide CLUE.IO FDA Orange Book: ifosfamide	CHEMBL124 PubChem??ifosfamide??
imatinib	Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor	Launched	From PubMed: PubMed 29076384 PubMed 16122278 PubMed 30504305 FDA Labels: IMATINIB MESYLATE IMATINIB MESYLATE IMATINIB MESYLATE From EMA: Imatinib Accord (PDF) CLUE.IO FDA Orange Book: imatinib mesylate	CHEMBL941 PubChem??imatinib?? DB00619
indinavir	HIV protease inhibitor	Launched	From PubMed: PubMed 30000598 PubMed 31643985 PubMed 11148725 FDA Labels: CRIXIVAN From EMA: Crixivan (PDF) CLUE.IO FDA Orange Book: indinavir sulfate	CHEMBL115 PubChem??indinavir?? DB00224
irinotecan	topoisomerase inhibitor	Launched	From PubMed: PubMed 29520731 PubMed 31415916 PubMed 33356422 FDA Labels: Irinotecan hydrochloide From EMA: Onivyde pegylated liposomal (previously known as Onivyde) (PDF) CLUE.IO FDA Orange Book: irinotecan hydrochloride	CHEMBL481 PubChem??irinotecan?? DB00762
isotretinoin	retinoid receptor agonist	Launched	From PubMed: PubMed 32744074 PubMed 32107726 PubMed 28291553 FDA Labels: CLUE.IO FDA Orange Book: isotretinoin	CHEMBL547 PubChem??isotretinoin?? DB00982
itraconazole	cytochrome P450 inhibitor	Launched	From PubMed: PubMed 11249550 PubMed 31142947 PubMed 34160825 FDA Labels: Itraconazole CICLOPIROX 3% / ITRACONAZOLE 5% / UREA 20% FLUCONAZOLE 4% / IBUPROFEN 2% / ITRACONAZOLE 1% / TERBINAFINE HCL 4% From EMA: Fungitraxx (PDF) CLUE.IO FDA Orange Book: itraconazole	CHEMBL1835950 PubChem??itraconazole?? DB1167
ivacaftor	CFTR channel potentiator	Launched	From PubMed: PubMed 31697873 PubMed 31784874 PubMed 30507114 From EMA: Kaftrio (PDF) CLUE.IO FDA Orange Book: ivacaftor	CHEMBL2010601 PubChem??ivacaftor?? DB08820
ketoconazole	sterol demethylase inhibitor	Launched	From PubMed: PubMed 31858672 PubMed 6301794 PubMed 6325087 From EMA: Ketoconazole HRA (PDF) CLUE.IO FDA Orange Book: ketoconazole	CHEMBL295698 PubChem??ketoconazole?? DB05667
lansoprazole	ATPase inhibitor	Launched	From PubMed: PubMed 27782887 PubMed 14687806 PubMed 32701188 CLUE.IO FDA Orange Book: dexlansoprazole, lansoprazole	CHEMBL1201863 PubChem??lansoprazole?? DB05351
lapatinib	EGFR inhibitor	Launched	From PubMed: PubMed 30069757 PubMed 32678716 PubMed 33581774 FDA Labels: Lapatinib From EMA: Tyverb (PDF) CLUE.IO FDA Orange Book: lapatinib ditosylate	CHEMBL554 PubChem??lapatinib?? DB01259
loratadine	histamine receptor antagonist	Launched	From PubMed: PubMed 32312261 PubMed 35396016 PubMed 31338198 From EMA: Neoclarityn (PDF) CLUE.IO FDA Orange Book: desloratadine, loratadine	CHEMBL998 PubChem??loratadine?? DB00455
lovastatin	HMGCR inhibitor	Launched	From PubMed: PubMed 31207306 PubMed 34438015 PubMed 32555902 FDA Labels: Lovastatin Advicor CLUE.IO FDA Orange Book: lovastatin	CHEMBL503 PubChem??lovastatin?? DB00227
maraviroc	CC chemokine receptor antagonist	Launched	From PubMed: PubMed 31643590 PubMed 30000615 PubMed 17927288 From EMA: Celsentri (PDF) CLUE.IO FDA Orange Book: maraviroc	CHEMBL1201187 PubChem??maraviroc?? DB04835
metronidazole	DNA inhibitor	Launched	From PubMed: PubMed 29077920 PubMed 25223673 PubMed 9360057 CLUE.IO FDA Orange Book: metronidazole, metronidazole hydrochloride	CHEMBL137 PubChem??metronidazole?? DB00916
mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	Launched	From PubMed: PubMed 26241251 PubMed 32853559 PubMed 11408990 FDA Labels: Mifepristone CLUE.IO FDA Orange Book: mifepristone	CHEMBL1276308 PubChem??mifepristone?? DB00834
nefazodone	adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin receptor antagonist, serotonin reuptake inhibitor	Withdrawn	From PubMed: PubMed 31643507 PubMed 30000248 PubMed 8748566 FDA Labels: CLUE.IO Wikipedia	CHEMBL623 PubChem??nefazodone?? DB01149
nelfinavir	HIV protease inhibitor	Launched	From PubMed: PubMed 30000597 PubMed 31643634 PubMed 9211082 FDA Labels: Viracept From EMA: Viracept (PDF) CLUE.IO FDA Orange Book: nelfinavir mesylate	CHEMBL584 PubChem??nelfinavir?? DB00220
nevirapine	non-nucleoside reverse transcriptase inhibitor	Launched	From PubMed: PubMed 20020271 PubMed 16734954 PubMed 33241266 FDA Labels: Nevirapine nevirapine From EMA: Viramune (PDF) CLUE.IO FDA Orange Book: nevirapine	CHEMBL57 PubChem??nevirapine?? DB00238
nifedipine	calcium channel blocker	Launched	From PubMed: PubMed 33154284 PubMed 6350496 PubMed 3890507 FDA Labels: Nifedipine CLUE.IO FDA Orange Book: nifedipine	CHEMBL193 PubChem??nifedipine?? DB01115
nisoldipine	calcium channel blocker	Launched	From PubMed: PubMed 30000110 PubMed 31643685 PubMed 3154674 FDA Labels: Nisoldipine CLUE.IO FDA Orange Book: nisoldipine	CHEMBL1726 PubChem??nisoldipine?? DB41
ondansetron	serotonin receptor antagonist	Launched	From PubMed: PubMed 7586904 PubMed 8427720 PubMed 8635834 CLUE.IO FDA Orange Book: ondansetron, ondansetron hydrochloride	CHEMBL428411 PubChem??ondansetron?? DB94
oxcarbazepine	sodium channel blocker	Launched	From PubMed: PubMed 30000302 PubMed 31643733 PubMed 33334546 FDA Labels: OXCARBAZEPINE CLUE.IO FDA Orange Book: oxcarbazepine	CHEMBL1068 PubChem??oxcarbazepine?? DB00776
PF-4981517	cytochrome P450 inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL3527048 PubChem??PF-4981517??
phenylbutyrate	HDAC inhibitor	Launched	From PubMed: PubMed 32877582 PubMed 31643305 PubMed 33063909 FDA Labels: Sodium Phenylbutyrate From EMA: Ammonaps (PDF) CLUE.IO FDA Orange Book: sodium phenylbutyrate	CHEMBL1469 PubChem??phenylbutyrate?? DB06819
pimecrolimus	calcineurin inhibitor	Launched	From PubMed: PubMed 30000478 PubMed 31053034 PubMed 23461536 FDA Labels: pimecrolimus CLUE.IO FDA Orange Book: pimecrolimus	PubChem??pimecrolimus?? DB337
ponatinib	Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor	Launched	From PubMed: PubMed 28969556 PubMed 31643461 PubMed 29567798 FDA Labels: Iclusig From EMA: Iclusig (PDF) CLUE.IO FDA Orange Book: ponatinib hydrochloride	CHEMBL1171837 PubChem??ponatinib?? DB08901
prasugrel	purinergic receptor antagonist	Launched	From PubMed: PubMed 31475799 PubMed 32334703 PubMed 33213722 FDA Labels: Prasugrel Prasugrel From EMA: Efient (PDF) CLUE.IO FDA Orange Book: prasugrel hydrochloride	CHEMBL121772 PubChem??prasugrel?? DB629
repaglinide	insulin secretagogue	Launched	From PubMed: PubMed 30000151 PubMed 31644186 PubMed 9739505 FDA Labels: Prandin From EMA: Repaglinide Krka (PDF) CLUE.IO FDA Orange Book: repaglinide	CHEMBL1272 PubChem??repaglinide?? DB00912
rifampin	RNA polymerase inhibitor	Launched	From PubMed: PubMed 28803492 PubMed 30455229 PubMed 4622757 FDA Labels: Rifampin CLUE.IO FDA Orange Book: rifampin	CHEMBL1332716 PubChem??rifampin?? DB145
rilpivirine	non-nucleoside reverse transcriptase inhibitor	Launched	From PubMed: PubMed 30000877 PubMed 32495274 PubMed 31643832 From EMA: Eviplera (PDF) CLUE.IO FDA Orange Book: rilpivirine hydrochloride	CHEMBL175691 PubChem??rilpivirine?? DB08864
risperidone	dopamine receptor antagonist, serotonin receptor antagonist	Launched	From PubMed: PubMed 25943458 PubMed 29695153 PubMed 22469322 From EMA: Okedi (PDF) CLUE.IO FDA Orange Book: risperidone	CHEMBL85 PubChem??risperidone?? DB00734
ritonavir	HIV protease inhibitor	Launched	From PubMed: PubMed 33031764 PubMed 35305258 PubMed 32918656 From EMA: Paxlovid (PDF) CLUE.IO FDA Orange Book: ritonavir	CHEMBL163 PubChem??ritonavir?? DB00503
rivaroxaban	coagulation factor inhibitor	Launched	From PubMed: PubMed 32222135 PubMed 33196155 PubMed 30002145 From EMA: Xarelto (PDF) CLUE.IO FDA Orange Book: rivaroxaban	CHEMBL198362 PubChem??rivaroxaban?? DB06228
romidepsin	HDAC inhibitor	Launched	From PubMed: PubMed 31643701 PubMed 33171487 PubMed 32013816 From EMA: Istodax (PDF) CLUE.IO FDA Orange Book: romidepsin	CHEMBL343448 PubChem??romidepsin??
saquinavir	HIV protease inhibitor	Launched	From PubMed: PubMed 30000592 PubMed 31643351 PubMed 8875367 FDA Labels: Invirase From EMA: Invirase (PDF) CLUE.IO FDA Orange Book: saquinavir, saquinavir mesylate	CHEMBL114 PubChem??saquinavir?? DB01232
saxagliptin	dipeptidyl peptidase inhibitor	Launched	From PubMed: PubMed 30000710 PubMed 31643998 PubMed 23992601 FDA Labels: ONGLYZA ONGLYZA QTERN From EMA: Komboglyze (PDF) CLUE.IO FDA Orange Book: saxagliptin hydrochloride	PubChem??saxagliptin?? DB07465
simvastatin	HMGCR inhibitor	Launched	From PubMed: PubMed 15571475 PubMed 33877804 PubMed 19968571 FDA Labels: VYTORIN From EMA: Cholib (PDF) CLUE.IO FDA Orange Book: simvastatin	CHEMBL1064 PubChem??simvastatin?? DB00641
sorafenib	FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor	Launched	From PubMed: PubMed 32532960 PubMed 31918403 PubMed 30575484 FDA Labels: Nexavar Sorafenib Tosylate From EMA: Nexavar (PDF) CLUE.IO FDA Orange Book: sorafenib tosylate	CHEMBL1336 PubChem??sorafenib?? DB00398
tacrolimus	calcineurin inhibitor	Launched	From PubMed: PubMed 29298646 PubMed 8787947 PubMed 29380698 FDA Labels: Tacrolimus NIACINAMIDE 4% / TACROLIMUS 0.03% HYALURONIC ACID SODIUM SALT 1% / TACROLIMUS 0.1% / UREA 20% Prograf From EMA: Modigraf (PDF) CLUE.IO FDA Orange Book: tacrolimus	CHEMBL269732 PubChem??tacrolimus?? DB00864
tamoxifen	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	Launched	From PubMed: PubMed 27152880 PubMed 29801584 PubMed 12612646 FDA Labels: CLUE.IO FDA Orange Book: tamoxifen citrate	CHEMBL83 PubChem??tamoxifen?? DB00675
telithromycin	bacterial 30S ribosomal subunit inhibitor, bacterial 50S ribosomal subunit inhibitor	Launched	From PubMed: PubMed 29999748 PubMed 31643912 PubMed 15257629 FDA Labels: Ketek From EMA: Ketek (PDF) CLUE.IO FDA Orange Book: telithromycin	PubChem??telithromycin??
teniposide	topoisomerase inhibitor	Launched	From PubMed: PubMed 1411642 PubMed 29604436 PubMed 3297462 CLUE.IO FDA Orange Book: teniposide	CHEMBL452231 PubChem??teniposide?? DB00444
thalidomide	tumor necrosis factor production inhibitor	Launched	From PubMed: PubMed 15172781 PubMed 30335598 PubMed 34779533 FDA Labels: Thalomid From EMA: Thalidomide Lipomed (PDF) CLUE.IO FDA Orange Book: thalidomide	CHEMBL426123 PubChem??thalidomide?? DB141
ticagrelor	purinergic receptor antagonist	Launched	From PubMed: PubMed 34708996 PubMed 32668111 PubMed 31475799 FDA Labels: ticagrelor From EMA: Brilique (PDF) CLUE.IO FDA Orange Book: ticagrelor	CHEMBL398435 PubChem??ticagrelor?? DB08816
toremifene	estrogen receptor antagonist, selective estrogen receptor modulator (SERM)	Launched	From PubMed: PubMed 31643660 PubMed 9097128 PubMed 25114854 FDA Labels: toremifene citrate From EMA: Fareston (PDF) CLUE.IO FDA Orange Book: toremifene citrate	CHEMBL1655 PubChem??toremifene?? DB00539
triamcinolone-acetonide	glucocorticoid receptor agonist, immunosuppressant	Launched	From PubMed: PubMed 30847805 PubMed 33043381 PubMed 16763379 CLUE.IO FDA Orange Book: triamcinolone acetonide	CHEMBL1504 PubChem??triamcinolone-acetonide?? DB62
vardenafil	phosphodiesterase inhibitor	Launched	From PubMed: PubMed 32697456 PubMed 31644226 PubMed 12027779 FDA Labels: Vardenafil Hydrochloride VARDENAFIL HYDROCHLORIDE VARDENAFIL HYDROCHLORIDE From EMA: Vivanza (PDF) CLUE.IO FDA Orange Book: vardenafil hydrochloride	CHEMBL1520 PubChem??vardenafil?? DB00862
veledimex	cytochrome P450 inhibitor	Phase 2	From PubMed: PubMed 27364771 PubMed 31413142 CLUE.IO ClinicalTrials	CHEMBL3039523 PubChem??veledimex?? DB12170
vemurafenib	RAF inhibitor	Launched	From PubMed: PubMed 30069761 PubMed 32558291 PubMed 29999925 FDA Labels: ZELBORAF From EMA: Zelboraf (PDF) CLUE.IO FDA Orange Book: vemurafenib	CHEMBL1229517 PubChem??vemurafenib?? DB08881
verapamil	calcium channel blocker	Launched	From PubMed: PubMed 31339562 PubMed 3530300 PubMed 30447294 FDA Labels: Trandolapril and Verapamil Hydrochloride CLUE.IO FDA Orange Book: verapamil hydrochloride	CHEMBL6966 PubChem??verapamil?? DB00661
voriconazole	cytochrome P450 inhibitor	Launched	From PubMed: PubMed 33549194 PubMed 16802848 PubMed 26684607 FDA Labels: Voriconazole From EMA: Vfend (PDF) CLUE.IO FDA Orange Book: voriconazole	CHEMBL638 PubChem??voriconazole?? DB00582
vortioxetine	serotonin receptor agonist, serotonin receptor antagonist	Launched	From PubMed: PubMed 29189941 PubMed 29149828 PubMed 31644061 FDA Labels: Trintellix From EMA: Brintellix (PDF) CLUE.IO FDA Orange Book: vortioxetine hydrobromide	CHEMBL2104993 PubChem??vortioxetine?? DB09068

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P20815}

Subcellular Locations ^{Source UniProt P20815}

Biological Processes ^{Source UniProt P20815}

KEGG hsa:1577 ^{Source UniProt P20815}

Reactome Pathways ^{Source UniProt P20815}

R-HSA-211981, Xenobiotics
R-HSA-5423646, Aflatoxin activation and detoxification

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
methyl-aminolevulinate	oxidizing agent	Launched	From PubMed: PubMed 15109276 PubMed 32212271 PubMed 24891062 CLUE.IO FDA Orange Book: methyl aminolevulinate hydrochloride	CHEMBL1096562 PubChem??methyl-aminolevulinate?? DB00992

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt C9JSN8}

Subcellular Locations ^{Source UniProt C9JSN8}

integral component of membrane

Biological Processes ^{Source UniProt C9JSN8}

KEGG ^{Source UniProt C9JSN8}

Reactome Pathways ^{Source UniProt C9JSN8}

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
AGI-6780	isocitrate dehydrogenase inhibitor	Preclinical	From PubMed: PubMed 27292784 CLUE.IO	CHEMBL3392845 PubChem: 71299339

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P48735}

Subcellular Locations ^{Source UniProt P48735}

Biological Processes ^{Source UniProt P48735}

KEGG hsa:3418 ^{Source UniProt P48735}

Reactome Pathways ^{Source UniProt P48735}

R-HSA-2151201, Transcriptional activation of mitochondrial biogenesis
R-HSA-71403, Citric acid cycle (TCA cycle)

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
integrin-antagonist-1	integrin antagonist	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	PubChem??integrin-antagonist-1??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P18564}

Subcellular Locations ^{Source UniProt P18564}

Biological Processes ^{Source UniProt P18564}

KEGG hsa:3694 ^{Source UniProt P18564}

Reactome Pathways ^{Source UniProt P18564}

R-HSA-1566948, Elastic fibre formation
R-HSA-2129379, Molecules associated with elastic fibres
R-HSA-216083, Integrin cell surface interactions
R-HSA-3000178, ECM proteoglycans

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
marimastat	matrix metalloprotease inhibitor	Phase 3	From PubMed: PubMed 12757409 PubMed 10357560 PubMed 11093361 CLUE.IO ClinicalTrials	CHEMBL279785 PubChem??marimastat?? DB00786

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P09237}

Subcellular Locations ^{Source UniProt P09237}

Biological Processes ^{Source UniProt P09237}

KEGG hsa:4316 ^{Source UniProt P09237}

Reactome Pathways ^{Source UniProt P09237}

R-HSA-1442490, Collagen degradation
R-HSA-1474228, Degradation of the extracellular matrix
R-HSA-1592389, Activation of Matrix Metalloproteinases
R-HSA-2022090, Assembly of collagen fibrils and other multimeric structures
R-HSA-9009391, Extra-nuclear estrogen signaling

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
AZD5153	bromodomain inhibitor	Phase 1	From PubMed: PubMed 33574760 CLUE.IO ClinicalTrials	CHEMBL4078100 PubChem: 118693659
mivebresib	bromodomain inhibitor	Phase 1	From PubMed: PubMed 33934351 PubMed 31420359 PubMed 34591474 CLUE.IO ClinicalTrials	CHEMBL3987016 PubChem??mivebresib??
TWS-119	glycogen synthase kinase inhibitor	Preclinical	From PubMed: PubMed 33582150 CLUE.IO	CHEMBL405759 PubChem??TWS-119??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P01106}

Subcellular Locations ^{Source UniProt P01106}

Biological Processes ^{Source UniProt P01106}

KEGG hsa:4609 ^{Source UniProt P01106}

Reactome Pathways ^{Source UniProt P01106}

R-HSA-1362277, Transcription of E2F targets under negative control by DREAM complex
R-HSA-201556, Signaling by ALK
R-HSA-2122947, NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-2173796, SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
R-HSA-2644606, Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-2894862, Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-4411364, Binding of TCF/LEF:CTNNB1 to target gene promoters
R-HSA-5687128, MAPK6/MAPK4 signaling
R-HSA-5689880, Ub-specific processing proteases
R-HSA-6785807, Interleukin-4 and Interleukin-13 signaling
R-HSA-69202, Cyclin E associated events during G1/S transition
R-HSA-69656, Cyclin A:Cdk2-associated events at S phase entry
R-HSA-8866911, TFAP2 (AP-2) family regulates transcription of cell cycle factors
R-HSA-8951430, RUNX3 regulates WNT signaling
R-HSA-9018519, Estrogen-dependent gene expression
R-HSA-9616222, Transcriptional regulation of granulopoiesis

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
brigatinib	ALK tyrosine kinase receptor inhibitor, EGFR inhibitor	Launched	From PubMed: PubMed 30280657 PubMed 32780660 PubMed 34537440 From EMA: Alunbrig (PDF) CLUE.IO DailyMed	CHEMBL3545311 PubChem: 68165256 DB12267
crizotinib	ALK tyrosine kinase receptor inhibitor	Launched	From PubMed: PubMed 33207094 PubMed 28586279 PubMed 30280657 FDA Labels: Xalkori From EMA: Xalkori (PDF) CLUE.IO FDA Orange Book: crizotinib	CHEMBL601719 PubChem: 11626560 DB08865
entrectinib	ALK tyrosine kinase receptor inhibitor, proto-oncogene tyrosine protein kinase inhibitor	Launched	From PubMed: PubMed 34633782 PubMed 32223357 PubMed 31372957 FDA Labels: Rozlytrek From EMA: Rozlytrek (PDF) CLUE.IO ClinicalTrials	CHEMBL1983268 PubChem: 25141092 DB11986
lorlatinib	ALK tyrosine kinase receptor inhibitor	Launched	From PubMed: PubMed 33207094 PubMed 31643879 PubMed 30601608 FDA Labels: Lorbrena From EMA: Lorviqua (PDF) CLUE.IO DailyMed	CHEMBL328683 PubChem??lorlatinib??
PF-06463922	ALK tyrosine kinase receptor inhibitor	Launched	From PubMed: PubMed 33207094 PubMed 33494549 PubMed 30892989 CLUE.IO ClinicalTrials	PubChem??PF-06463922??
repotrectinib	receptor tyrosine protein kinase inhibitor	Phase 1/Phase 2	From PubMed: PubMed 31738426 PubMed 34563714 PubMed 31720561 CLUE.IO ClinicalTrials	PubChem??repotrectinib??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P08922}

Subcellular Locations ^{Source UniProt P08922}

Biological Processes ^{Source UniProt P08922}

KEGG hsa:6098 ^{Source UniProt P08922}

Reactome Pathways ^{Source UniProt P08922}

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
17-hydroxyprogesterone-caproate	progesterone receptor agonist	Launched	From PubMed: PubMed 30339274 PubMed 26663620 PubMed 33487666 CLUE.IO FDA Orange Book: hydroxyprogesterone caproate	CHEMBL1200848 PubChem: 169870 DB06789
2-hydroxyflutamide	androgen receptor antagonist	Phase 2	From PubMed: PubMed 28736321 PubMed 25055161 PubMed 29214142 CLUE.IO ClinicalTrials	CHEMBL491 PubChem: 91649
3,3'-diindolylmethane	CHK inhibitor, cytochrome P450 activator, indoleamine 2,3-dioxygenase inhibitor	Phase 3	From PubMed: PubMed 34660663 PubMed 27447608 PubMed 32458980 CLUE.IO ClinicalTrials	CHEMBL446452 PubChem: 3071 DB11875
4-methylgenistein	protein tyrosine kinase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL131921 PubChem: 5280373 DB15334
andarine	androgen receptor modulator	Phase 1	From PubMed: PubMed 26909454 PubMed 30688367 PubMed 19683376 CLUE.IO Springer	CHEMBL125236 PubChem: 9824562 DB07423
apalutamide	androgen receptor antagonist	Launched	From PubMed: PubMed 31150574 PubMed 32907777 PubMed 29420164 FDA Labels: ERLEADA From EMA: Erleada (PDF) CLUE.IO FDA Orange Book: apalutamide	CHEMBL3183409 PubChem: 24872560 DB11901
APC-100	androgen receptor antagonist, anti-inflammatory agent	Phase 1/Phase 2	From PubMed: PubMed 26924129 CLUE.IO ClinicalTrials	CHEMBL37676 PubChem: 99479 DB13111
apigenin	casein kinase inhibitor, cell proliferation inhibitor	Preclinical	From PubMed: PubMed 30875872 PubMed 32059077 PubMed 32660399 CLUE.IO	CHEMBL28 PubChem: 5280443 DB07352
ASC-J9	androgen receptor enhancer	Phase 2	From PubMed: PubMed 33277796 PubMed 23687298 PubMed 22668795 CLUE.IO ClinicalTrials	CHEMBL261295 PubChem: 74891315
AZD3514	androgen receptor modulator	Phase 1	From PubMed: PubMed 25920479 PubMed 26876616 PubMed 25708954 CLUE.IO ClinicalTrials	CHEMBL2346976 PubChem: 46893585
bicalutamide	androgen receptor antagonist	Launched	From PubMed: PubMed 31643303 PubMed 33496795 PubMed 26811535 FDA Labels: bicalutamide CLUE.IO FDA Orange Book: bicalutamide	CHEMBL409 PubChem: 2375 DB01128
bisphenol-A	synthetic estrogen	Phase 1	From PubMed: PubMed 32171313 PubMed 29229539 PubMed 32114652 CLUE.IO ClinicalTrials	CHEMBL418971 PubChem: 6623 DB06973
CB-03-01	androgen receptor antagonist	Phase 3	From PubMed: PubMed 32320027 PubMed 33409936 PubMed 33030710 CLUE.IO ClinicalTrials	CHEMBL3590187 PubChem: 11750009 DB12499
clomifene	estrogen receptor antagonist	Launched	From PubMed: PubMed 30522888 PubMed 19809318 PubMed 25006718 From EMA: EnCyzix (PDF) CLUE.IO drugs.com	CHEMBL167779 PubChem: 1548955 DB882
cortodoxone	androgen receptor antagonist	Phase 3	From PubMed: PubMed 31393195 PubMed 33030710 PubMed 31450227 CLUE.IO ClinicalTrials	CHEMBL253144 PubChem: 440707
cyproterone-acetate	androgen receptor antagonist	Launched	From PubMed: PubMed 14583927 PubMed 34274044 PubMed 28463030 CLUE.IO ClinicalTrials	CHEMBL139835 PubChem: 9880 DB04839
danazol	estrogen receptor antagonist, progesterone receptor agonist	Launched	From PubMed: PubMed 2486535 PubMed 7041729 PubMed 17253444 FDA Labels: Danazol CLUE.IO FDA Orange Book: danazol	CHEMBL1479 PubChem: 28417 DB01406
darolutamide	androgen receptor antagonist	Launched	From PubMed: PubMed 30763142 PubMed 32905676 PubMed 35179323 FDA Labels: NUBEQA From EMA: Nubeqa (PDF) CLUE.IO FDA Orange Book: darolutamide	PubChem: 121489720
dehydroepiandrosterone	protein synthesis stimulant	Launched	From PubMed: PubMed 30029723 PubMed 25022952 PubMed 27927044 FDA Labels: Hormone Combination Hormone Harmony Professional Weight Support Weight Management Hormone Balance Professional Weight Maintenance HA2CG Evolution CLUE.IO ClinicalTrials	CHEMBL90593 PubChem: 5881 DB01708
dehydroepiandrosterone-sulfate	androgen receptor agonist, estrogen receptor agonist	Launched	From PubMed: PubMed 34523302 PubMed 32692055 PubMed 21478748 CLUE.IO Wikipedia	CHEMBL259898 PubChem: 12594 DB05804
dromostanolone-propionate	androgen receptor modulator	Launched	From PubMed: PubMed 6293073 CLUE.IO FDA	PubChem:
drospirenone	mineralocorticoid receptor antagonist	Launched	From PubMed: PubMed 30000415 PubMed 32538188 PubMed 33155847 From EMA: Lydisilka (PDF) CLUE.IO FDA Orange Book: drospirenone	CHEMBL1509 PubChem: 68873 DB01395
enzalutamide	androgen receptor antagonist	Launched	From PubMed: PubMed 31157964 PubMed 32469184 PubMed 29949494 FDA Labels: Xtandi From EMA: Xtandi (PDF) CLUE.IO FDA Orange Book: enzalutamide	CHEMBL1082407 PubChem: 15951529 DB08899
epitiostanol	androgen receptor agonist	Launched	From PubMed: PubMed 6372698 CLUE.IO Wikipedia	CHEMBL2106161 PubChem: 443935
eugenol	androgen receptor antagonist	Launched	From PubMed: PubMed 27771920 PubMed 31869191 PubMed 34885992 FDA Labels: Marshall Toothache Drops Dry Socket TotalArthritis PainONil Oligo Bio Iodine CLUE.IO drugs.com	CHEMBL42710 PubChem: 3314 DB09086
finasteride	5 alpha reductase inhibitor	Launched	From PubMed: PubMed 28393993 PubMed 29447628 PubMed 26924401 FDA Labels: Finasteride ENTADFI FINASTERIDE 0.1% / MINOXIDIL 7% / TRETINOIN 0.025% DEXAMETHASONE SODIUM PHOSPHATE 0.1% / FINASTERIDE 0.1% / MINOXIDIL 5% / TRETINOIN 0.025% CLUE.IO FDA Orange Book: finasteride	CHEMBL710 PubChem: 57363 DB01216
flufenamic-acid	chloride channel blocker	Preclinical	From PubMed: PubMed 23356979 PubMed 4895010 PubMed 7021261 CLUE.IO	CHEMBL23588 PubChem: 3371 DB02266
flutamide	androgen receptor antagonist	Launched	From PubMed: PubMed 28379593 PubMed 29958919 PubMed 2193461 FDA Labels: Flutamide CLUE.IO FDA Orange Book: flutamide	CHEMBL806 PubChem: 3397 DB00499
galeterone	androgen receptor modulator	Phase 3	From PubMed: PubMed 27486306 PubMed 31542304 PubMed 26527750 CLUE.IO ClinicalTrials	CHEMBL2105738 PubChem: 11188409 DB12415
gestrinone	progesterone receptor antagonist	Launched	From PubMed: PubMed 28742263 PubMed 24610050 PubMed 2205289 CLUE.IO drugs.com	CHEMBL1868702 PubChem: 27812 DB11619
GLPG0492	androgen receptor modulator	Phase 1	From PubMed: PubMed 28137616 CLUE.IO ClinicalTrials	CHEMBL2178100 PubChem: 59317190 DB12461
GLPG0492-R-enantiomer	androgen receptor modulator	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL2178101 PubChem: 59317173
GSK2881078	androgen receptor modulator	Phase 2	From PubMed: PubMed 29982690 PubMed 28449232 CLUE.IO ClinicalTrials	PubChem: 86709174
kaempferol	bone resorption inhibitor, estrogen-related receptor inverse agonist	Preclinical	From PubMed: PubMed 31248102 PubMed 31557798 PubMed 31572524 CLUE.IO	CHEMBL150 PubChem??kaempferol?? DB01852
ketoconazole	sterol demethylase inhibitor	Launched	From PubMed: PubMed 31858672 PubMed 6301794 PubMed 6325087 From EMA: Ketoconazole HRA (PDF) CLUE.IO FDA Orange Book: ketoconazole	CHEMBL295698 PubChem??ketoconazole?? DB05667
LXR-623	LXR agonist	Phase 1	From PubMed: PubMed 25523004 PubMed 19398602 PubMed 34703267 CLUE.IO ClinicalTrials	CHEMBL456237 PubChem??LXR-623??
LY2452473	androgen receptor modulator	Phase 2	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL3542265 PubChem??LY2452473?? DB12573
mifepristone	glucocorticoid receptor antagonist, progesterone receptor antagonist	Launched	From PubMed: PubMed 26241251 PubMed 32853559 PubMed 11408990 FDA Labels: Mifepristone CLUE.IO FDA Orange Book: mifepristone	CHEMBL1276308 PubChem??mifepristone?? DB00834
MK-0773	androgen receptor modulator	Phase 2	From PubMed: PubMed 28137616 PubMed 23732550 PubMed 24189892 CLUE.IO ClinicalTrials	CHEMBL3221237 PubChem??MK-0773??
myricetin	androgen receptor agonist, cytochrome P450 inhibitor	Preclinical	From PubMed: PubMed 33338751 PubMed 34646551 PubMed 32877951 CLUE.IO	CHEMBL164 PubChem??myricetin?? DB02375
nilutamide	androgen receptor antagonist	Launched	From PubMed: PubMed 31643487 PubMed 8997470 PubMed 8453188 FDA Labels: Nilutamide CLUE.IO FDA Orange Book: nilutamide	CHEMBL1274 PubChem??nilutamide?? DB00665
norgestrel	progesterone receptor agonist	Launched	From PubMed: PubMed 7438754 PubMed 29637798 PubMed 34499877 CLUE.IO FDA Orange Book: levonorgestrel, norgestrel	CHEMBL1389 PubChem??norgestrel?? DB00367
ostarine	androgen receptor modulator	Phase 3	From PubMed: PubMed 34445197 PubMed 19852734 PubMed 28137616 CLUE.IO ClinicalTrials	CHEMBL1738889 PubChem??ostarine?? DB12078
PF-06260414	androgen receptor modulator	Phase 1	From PubMed: PubMed 27085586 CLUE.IO ClinicalTrials	PubChem??PF-06260414?? DB15221
pinocembrin	cytochrome P450 inhibitor	Phase 2	From PubMed: PubMed 29642511 PubMed 31238565 PubMed 23984355 CLUE.IO ClinicalTrials	CHEMBL399910 PubChem??pinocembrin??
PS178990	androgen receptor modulator	Phase 1	From PubMed: No search result CLUE.IO drugs.com	CHEMBL229264 PubChem??PS178990?? DB07286
pyrvinium-pamoate	androgen receptor antagonist	Launched	From PubMed: PubMed 4608381 PubMed 28500633 PubMed 4618573 CLUE.IO FDA Orange Book: pyrvinium pamoate	CHEMBL1201303 PubChem??pyrvinium-pamoate?? DB06816
RAD140	androgen receptor modulator	Phase 1	From PubMed: PubMed 28137616 PubMed 34565686 CLUE.IO ClinicalTrials	CHEMBL1672635 PubChem??RAD140?? DB13939
RU-58841	androgen receptor antagonist	Phase 2	From PubMed: PubMed 18532922 CLUE.IO Pharmaprojects	CHEMBL9337 PubChem??RU-58841??
spironolactone	mineralocorticoid receptor antagonist	Launched	From PubMed: PubMed 24716680 PubMed 32844462 PubMed 28024992 FDA Labels: Spironolactone Spironolactone and Hydrochlorothiazide 011218 NIACINAMIDE 2% / SPIRONOLACTONE 5% / TRETINOIN 0.025% 011220 NIACINAMIDE 2% / SPIRONOLACTONE 5% / TRETINOIN 0.05% 011503 DAPSONE 6% / NIACINAMIDE 2% / SPIRONOLACTONE 5% BENZOYL PEROXIDE 5% / CLINDAMYCIN 1% / NIACINAMIDE 2% / SPIRONOLACTONE 2% BENZOYL PEROXIDE 5% / CLINDAMYCIN 1% / NIACINAMIDE 2% / SPIRONOLACTONE 2% / TRETINOIN 0.025% GUNA-DIUR From EMA: Cardalis (PDF) CLUE.IO FDA Orange Book: spironolactone	CHEMBL1393 PubChem??spironolactone?? DB00421
stetaderm	NA	Launched	From PubMed: PubMed 31565952 PubMed 30958285 PubMed 28209175 CLUE.IO Pharmaprojects	CHEMBL1563246 PubChem??stetaderm??
tibolone	androgen receptor agonist, estrogen receptor agonist, progesterone receptor agonist	Launched	From PubMed: PubMed 27733017 PubMed 32507541 PubMed 15035189 CLUE.IO drugs.com	PubChem??tibolone??
topilutamide	androgen receptor antagonist	Preclinical	From PubMed: PubMed 28636139 CLUE.IO	PubChem??topilutamide??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P10275}

Subcellular Locations ^{Source UniProt P10275}

Biological Processes ^{Source UniProt P10275}

KEGG hsa:367 ^{Source UniProt P10275}

Reactome Pathways ^{Source UniProt P10275}

R-HSA-3371497, HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
R-HSA-383280, Nuclear Receptor transcription pathway
R-HSA-4090294, SUMOylation of intracellular receptors
R-HSA-5625886, Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
R-HSA-5689880, Ub-specific processing proteases
R-HSA-8940973, RUNX2 regulates osteoblast differentiation

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
AZ20	ATR kinase inhibitor	Preclinical	From PubMed: PubMed 32114443 CLUE.IO	CHEMBL2325697 PubChem: 46244454
AZD6738	ATR kinase inhibitor	Phase 2	From PubMed: PubMed 34301752 PubMed 34710570 PubMed 29899559 CLUE.IO ClinicalTrials	CHEMBL3648328 PubChem: 54761305
BAY-1895344	ATR kinase inhibitor	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	PubChem: 118869362
caffeine	adenosine receptor antagonist, phosphodiesterase inhibitor	Launched	From PubMed: PubMed 30977054 PubMed 23075568 PubMed 28446037 From EMA: Gencebok (PDF) CLUE.IO FDA Orange Book: caffeine, caffeine citrate	CHEMBL113 PubChem: 2519 DB00201
CGK-733	ATM kinase inhibitor, ATR kinase inhibitor	Preclinical	From PubMed: PubMed 24795863 CLUE.IO	CHEMBL122161 PubChem: 92509770
NU-6027	CDK inhibitor	Preclinical	From PubMed: PubMed 29899559 CLUE.IO	CHEMBL303958 PubChem??NU-6027?? DB08312
NVP-BEZ235	mTOR inhibitor, PI3K inhibitor	Phase 3	From PubMed: PubMed 23215722 PubMed 30981885 PubMed 29604436 CLUE.IO Unexpected Source	CHEMBL1879463 PubChem??NVP-BEZ235?? DB11651
schisandrin-B	antioxidant	Preclinical	From PubMed: PubMed 32256947 PubMed 27847552 PubMed 22666518 CLUE.IO	CHEMBL513752 PubChem??schisandrin-B??
VE-821	ATR kinase inhibitor	Preclinical	From PubMed: PubMed 32109490 CLUE.IO	CHEMBL1766779 PubChem??VE-821??
VE-822	ATR kinase inhibitor	Phase 2	From PubMed: PubMed 29899559 PubMed 32109490 PubMed 32568634 CLUE.IO ClinicalTrials	CHEMBL3989870 PubChem??VE-822?? DB11794
wortmannin	PI3K inhibitor	Preclinical	From PubMed: PubMed 30981885 PubMed 7667888 PubMed 26827608 CLUE.IO	CHEMBL428496 PubChem??wortmannin?? DB08059

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt D6RIG7}

Subcellular Locations ^{Source UniProt D6RIG7}

Biological Processes ^{Source UniProt D6RIG7}

KEGG ^{Source UniProt D6RIG7}

Reactome Pathways ^{Source UniProt D6RIG7}

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
4,5,6,7-tetrabromobenzotriazole	casein kinase inhibitor	Preclinical	From PubMed: PubMed 16203192 PubMed 23416530 CLUE.IO	CHEMBL177820 PubChem: 1694 DB04462
7-hydroxystaurosporine	CDK inhibitor, CHK inhibitor, PKC inhibitor	Phase 2	From PubMed: PubMed 21745173 PubMed 10888035 PubMed 16293603 CLUE.IO ClinicalTrials	CHEMBL574737 PubChem: 3078519 DB1933
AZD7762	CHK inhibitor	Phase 1	From PubMed: PubMed 24448638 PubMed 23892959 PubMed 18694366 CLUE.IO ClinicalTrials	CHEMBL2041933 PubChem: 11152667 DB12242
BX-795	IKK inhibitor	Preclinical	From PubMed: PubMed 27693724 PubMed 34111484 PubMed 26293650 CLUE.IO	CHEMBL577784 PubChem: 10077147
BX-912	pyruvate dehydrogenase kinase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL3916849 PubChem: 11754511
CCT245737	kinase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	PubChem: 72165232
CHIR-124	CHK inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL377312 PubChem: 135399748 DB06852
GDC-0575	CHK inhibitor	Phase 1	From PubMed: PubMed 29788155 PubMed 29409053 CLUE.IO ClinicalTrials	PubChem: 46917793
KN-62	calcium/calmodulin dependent protein kinase inhibitor, purinergic receptor antagonist	Preclinical	From PubMed: PubMed 8783561 PubMed 33728582 PubMed 17584060 CLUE.IO	CHEMBL28324 PubChem??KN-62??
LY2603618	CHK inhibitor	Phase 2	From PubMed: PubMed 28202004 PubMed 27350064 PubMed 27598338 CLUE.IO ClinicalTrials	CHEMBL3039517 PubChem??LY2603618?? DB11662
LY2606368	CHK inhibitor	Phase 2	From PubMed: PubMed 34034991 PubMed 33881209 PubMed 32510664 CLUE.IO ClinicalTrials	CHEMBL3544911 PubChem??LY2606368?? DB12008
LY294002	DNA dependent protein kinase inhibitor, mTOR inhibitor, phosphodiesterase inhibitor, PI3K inhibitor, PLK inhibitor	Preclinical	From PubMed: PubMed 30981885 PubMed 28176634 PubMed 8791418 CLUE.IO	CHEMBL98350 PubChem??LY294002?? DB02656
PD-98059	MEK inhibitor	Preclinical	From PubMed: PubMed 16888671 PubMed 27115708 PubMed 18068683 CLUE.IO	CHEMBL35482 PubChem??PD-98059??
PF-477736	CHK inhibitor	Phase 1	From PubMed: PubMed 18694366 CLUE.IO ClinicalTrials	CHEMBL3990456 PubChem??PF-477736?? DB12611
SB-202190	p38 MAPK inhibitor	Preclinical	From PubMed: PubMed 10909084 CLUE.IO	CHEMBL278041 PubChem??SB-202190??
SB-203580	p38 MAPK inhibitor	Preclinical	From PubMed: PubMed 16888671 PubMed 16283677 PubMed 22260669 CLUE.IO	CHEMBL1 PubChem??SB-203580?? DB08521
SB-218078	CHK inhibitor	Preclinical	From PubMed: PubMed 15078995 CLUE.IO	CHEMBL304428 PubChem??SB-218078?? DB8683
SCH-900776	CHK inhibitor	Phase 2	From PubMed: PubMed 23092873 PubMed 32135247 PubMed 25605849 CLUE.IO ClinicalTrials	CHEMBL2386889 PubChem??SCH-900776?? DB11899
tanespimycin	HSP inhibitor	Phase 3	From PubMed: PubMed 21454186 PubMed 19466875 PubMed 31713482 CLUE.IO ClinicalTrials	CHEMBL1948 PubChem??tanespimycin??
U-0126	MEK inhibitor	Preclinical	From PubMed: PubMed 23603495 PubMed 20588026 PubMed 25673531 CLUE.IO	CHEMBL3474 PubChem??U-0126??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt O14757}

Subcellular Locations ^{Source UniProt O14757}

Biological Processes ^{Source UniProt O14757}

KEGG hsa:1111 ^{Source UniProt O14757}

Reactome Pathways ^{Source UniProt O14757}

R-HSA-1433557, Signaling by SCF-KIT
R-HSA-176187, Activation of ATR in response to replication stress
R-HSA-5693607, Processing of DNA double-strand break ends
R-HSA-5693616, Presynaptic phase of homologous DNA pairing and strand exchange
R-HSA-6796648, TP53 Regulates Transcription of DNA Repair Genes
R-HSA-6804756, Regulation of TP53 Activity through Phosphorylation
R-HSA-69473, G2/M DNA damage checkpoint
R-HSA-69601, Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
R-HSA-75035, Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
R-HSA-8953750, Transcriptional Regulation by E2F6

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
laquinimod	immunosuppressant	Phase 3	From PubMed: PubMed 24731945 PubMed 23922214 PubMed 27089834 From EMA: Nerventra (PDF) CLUE.IO ClinicalTrials	CHEMBL66092 PubChem??laquinimod?? DB06685

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P19875}

Subcellular Locations ^{Source UniProt P19875}

Biological Processes ^{Source UniProt P19875}

KEGG hsa:2920 ^{Source UniProt P19875}

Reactome Pathways ^{Source UniProt P19875}

R-HSA-380108, Chemokine receptors bind chemokines
R-HSA-418594, G alpha (i) signalling events
R-HSA-6783783, Interleukin-10 signaling

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
alexidine	phosphatidylglycerophosphatase inhibitor	Preclinical	From PubMed: PubMed 381628 PubMed 6947988 PubMed 264922 CLUE.IO	CHEMBL119521 PubChem: 40488318
ALX-40-4C	CC chemokine receptor antagonist	Preclinical	From PubMed: No search result CLUE.IO	PubChem: 25077385
AMD-3465	CC chemokine receptor antagonist	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL477121 PubChem: 483559
AMD11070	CC chemokine receptor antagonist	Phase 3	From PubMed: PubMed 33275726 PubMed 31903790 PubMed 31099252 CLUE.IO ClinicalTrials	CHEMBL518924 PubChem: 11256587 DB05501
IT1t	CC chemokine receptor antagonist	Preclinical	From PubMed: PubMed 26144264 CLUE.IO	CHEMBL460491 PubChem??IT1t??
LY2510924	CC chemokine receptor antagonist	Phase 2	From PubMed: PubMed 28643374 PubMed 24727324 PubMed 28236984 CLUE.IO ClinicalTrials	PubChem??LY2510924??
MSX-122	CC chemokine receptor antagonist	Phase 2	From PubMed: PubMed 22376154 CLUE.IO ClinicalTrials	CHEMBL3545330 PubChem??MSX-122?? DB12715
neomycin	bacterial 30S ribosomal subunit inhibitor	Launched	From PubMed: PubMed 4865737 PubMed 26700538 PubMed 8170691 CLUE.IO FDA Orange Book: neomycin sulfate	CHEMBL184618 PubChem??neomycin?? DB00452
plerixafor	CC chemokine receptor antagonist	Launched	From PubMed: PubMed 31643772 PubMed 25031928 PubMed 26554889 FDA Labels: Mozobil From EMA: Mozobil (PDF) CLUE.IO FDA Orange Book: plerixafor	CHEMBL18442 PubChem??plerixafor?? DB06809
WZ811	CC chemokine receptor antagonist	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL237830 PubChem??WZ811??

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P61073}

Subcellular Locations ^{Source UniProt P61073}

Biological Processes ^{Source UniProt P61073}

KEGG hsa:7852 ^{Source UniProt P61073}

Reactome Pathways ^{Source UniProt P61073}

R-HSA-173107, Binding and entry of HIV virion
R-HSA-376176, Signaling by ROBO receptors
R-HSA-380108, Chemokine receptors bind chemokines
R-HSA-418594, G alpha (i) signalling events

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
1400W	nitric oxide synthase inhibitor	Preclinical	From PubMed: PubMed 9736922 PubMed 10972817 PubMed 12204686 CLUE.IO	CHEMBL107251 PubChem: 1433 DB02044
2-iminobiotin	nitric oxide synthase inhibitor	Phase 2	From PubMed: PubMed 31960360 PubMed 31625480 PubMed 31578035 CLUE.IO ClinicalTrials	CHEMBL1233598 PubChem: 135678104 DB03353
3-bromo-7-nitroindazole	nitric oxide synthase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL479014 PubChem: 1649 DB01997
7-nitroindazole	nitric oxide synthase inhibitor	Preclinical	From PubMed: PubMed 32341976 PubMed 27015893 PubMed 15193032 CLUE.IO	CHEMBL247378 PubChem: 1893 DB02207
bendazol	nitric oxide synthase stimulant	Launched	From PubMed: PubMed 29386158 FDA Labels: Albendazole From EMA: Panacur AquaSol (PDF) CLUE.IO FDA Orange Book: bendazol	CHEMBL355063 PubChem: 12132
bismuth-subgallate	nitric oxide synthase inhibitor	Launched	From PubMed: PubMed 10772440 PubMed 20657853 PubMed 7745334 CLUE.IO Wikipedia	PubChem: 73415769 DB13909
C11-Acetate	NA	Phase 3	From PubMed: PubMed 21285676 PubMed 26277234 CLUE.IO ClinicalTrials	PubChem: 168049
flavin-adenine-dinucleotide	NA	Preclinical	From PubMed: PubMed 33279678 PubMed 21890489 PubMed 23680095 CLUE.IO	CHEMBL1232653 PubChem: 643975 DB03147
L-citrulline	nitric oxide stimulant	Launched	From PubMed: PubMed 30029482 PubMed 27749691 PubMed 31336573 CLUE.IO drugs.com	CHEMBL444814 PubChem??L-citrulline?? DB00155
L-monomethylarginine	nitric oxide synthase inhibitor	Phase 3	From PubMed: PubMed 27704594 PubMed 33621423 PubMed 31628700 CLUE.IO PubMed	CHEMBL332148 PubChem??L-monomethylarginine??
L-NIL	nitric oxide synthase inhibitor	Preclinical	From PubMed: PubMed 31409394 PubMed 19614613 PubMed 20359124 CLUE.IO	CHEMBL7889 PubChem??L-NIL??
myricitrin	PKC inhibitor	Preclinical	From PubMed: PubMed 30474534 PubMed 33838291 PubMed 29412767 CLUE.IO	CHEMBL522983 PubChem??myricitrin??
NG-nitro-arginine	nitric oxide synthase inhibitor	Phase 1	From PubMed: PubMed 16432054 PubMed 34380875 CLUE.IO ClinicalTrials	CHEMBL227744 PubChem??NG-nitro-arginine?? DB04223
proadifen	nitric oxide synthase inhibitor	Preclinical	From PubMed: PubMed 791803 PubMed 1094885 PubMed 768968 CLUE.IO	CHEMBL282567 PubChem??proadifen??
riboflavin-5-phosphate-sodium	NA	Launched	From PubMed: PubMed 21890489 PubMed 30680745 PubMed 33886098 CLUE.IO Wikipedia	CHEMBL1201794 PubChem??riboflavin-5-phosphate-sodium?? DB03247

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P29475}

Subcellular Locations ^{Source UniProt P29475}

Biological Processes ^{Source UniProt P29475}

KEGG hsa:4842 ^{Source UniProt P29475}

Reactome Pathways ^{Source UniProt P29475}

R-HSA-1222556, ROS and RNS production in phagocytes
R-HSA-392154, Nitric oxide stimulates guanylate cyclase
R-HSA-5578775, Ion homeostasis

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
1400W	nitric oxide synthase inhibitor	Preclinical	From PubMed: PubMed 9736922 PubMed 10972817 PubMed 12204686 CLUE.IO	CHEMBL107251 PubChem: 1433 DB02044
2-iminobiotin	nitric oxide synthase inhibitor	Phase 2	From PubMed: PubMed 31960360 PubMed 31625480 PubMed 31578035 CLUE.IO ClinicalTrials	CHEMBL1233598 PubChem: 135678104 DB03353
3-bromo-7-nitroindazole	nitric oxide synthase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL479014 PubChem: 1649 DB01997
7-nitroindazole	nitric oxide synthase inhibitor	Preclinical	From PubMed: PubMed 32341976 PubMed 27015893 PubMed 15193032 CLUE.IO	CHEMBL247378 PubChem: 1893 DB02207
aminoguanidine	nitric oxide synthase inhibitor	Phase 3	From PubMed: PubMed 9434471 PubMed 11270668 PubMed 12387057 CLUE.IO Wikipedia	CHEMBL225304 PubChem: 2146 DB05383
aminomethyltransferase	nitric oxide synthase inhibitor	Preclinical	From PubMed: PubMed 20301531 PubMed 16042597 PubMed 34111435 CLUE.IO	CHEMBL16322 PubChem: 7059445
aminothiazole	cyclin D inhibitor	Preclinical	From PubMed: PubMed 33148490 PubMed 33800023 PubMed 33469255 CLUE.IO	CHEMBL344760 PubChem: 2155
asymmetrical-dimethylarginine	nitric oxide synthase inhibitor	Phase 1	From PubMed: PubMed 27760067 PubMed 15096461 PubMed 32316894 CLUE.IO PubMed	CHEMBL457530 PubChem: 123831 DB01686
bardoxolone	nuclear factor erythroid derived, like (NRF2) activator	Phase 1	From PubMed: PubMed 24206459 PubMed 32594372 PubMed 31580543 CLUE.IO Springer	CHEMBL1093059 PubChem: 400010 DB12651
bendazol	nitric oxide synthase stimulant	Launched	From PubMed: PubMed 29386158 FDA Labels: Albendazole From EMA: Panacur AquaSol (PDF) CLUE.IO FDA Orange Book: bendazol	CHEMBL355063 PubChem: 12132
curcumin	cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor	Launched	From PubMed: PubMed 28074653 PubMed 24794906 PubMed 17999464 FDA Labels: Immune Support CLUE.IO ClinicalTrials	CHEMBL14 PubChem: 6971205
dexamethasone	glucocorticoid receptor agonist	Launched	From PubMed: PubMed 31595319 PubMed 31755076 PubMed 31416827 From EMA: Ozurdex (PDF) CLUE.IO FDA Orange Book: dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate	CHEMBL384467 PubChem: 5743 DB01234
diphenyleneiodonium	nitric oxide synthase inhibitor	Preclinical	From PubMed: PubMed 31434645 PubMed 23085520 PubMed 7003824 CLUE.IO	CHEMBL365739 PubChem:
EIT-hydrobromide	nitric oxide synthase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL321691 PubChem: 5139 DB02234
guanidinoethyldisulfide-bicarbonate	nitric oxide synthase inhibitor	Phase 2	From PubMed: No search result CLUE.IO Cortellis	CHEMBL105278 PubChem: 3521
GW274150	nitric oxide synthase inhibitor	Phase 2	From PubMed: PubMed 20974604 PubMed 22409880 PubMed 24818644 CLUE.IO ClinicalTrials	CHEMBL114551 PubChem??GW274150?? DB12237
HP-228	nitric oxide synthase inhibitor	Preclinical	From PubMed: PubMed 9512083 PubMed 17584134 CLUE.IO	PubChem??HP-228??
hydrocortisone	glucocorticoid receptor agonist	Launched	From PubMed: PubMed 30441816 PubMed 26916176 PubMed 32394073 From EMA: Plenadren (PDF) CLUE.IO FDA Orange Book: hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone cypionate, hydrocortisone probutate, hydrocortisone sodium phosphate, hydrocortisone sodium succinate, hydrocortisone valerate	CHEMBL389621 PubChem??hydrocortisone?? DB00741
L-arginine	nitric oxide precursor	Launched	From PubMed: PubMed 24755570 PubMed 30605863 PubMed 31336573 From EMA: LysaKare (PDF) CLUE.IO ClinicalTrials	CHEMBL1485 PubChem??L-arginine?? DB00125
L-citrulline	nitric oxide stimulant	Launched	From PubMed: PubMed 30029482 PubMed 27749691 PubMed 31336573 CLUE.IO drugs.com	CHEMBL444814 PubChem??L-citrulline?? DB00155
L-monomethylarginine	nitric oxide synthase inhibitor	Phase 3	From PubMed: PubMed 27704594 PubMed 33621423 PubMed 31628700 CLUE.IO PubMed	CHEMBL332148 PubChem??L-monomethylarginine??
L-NIL	nitric oxide synthase inhibitor	Preclinical	From PubMed: PubMed 31409394 PubMed 19614613 PubMed 20359124 CLUE.IO	CHEMBL7889 PubChem??L-NIL??
NG-nitro-arginine	nitric oxide synthase inhibitor	Phase 1	From PubMed: PubMed 16432054 PubMed 34380875 CLUE.IO ClinicalTrials	CHEMBL227744 PubChem??NG-nitro-arginine?? DB04223
nitroflurbiprofen	cyclooxygenase inhibitor	Preclinical	From PubMed: PubMed 15202730 PubMed 15470334 PubMed 15850679 CLUE.IO	PubChem??nitroflurbiprofen??
spermine	NA	Preclinical	From PubMed: PubMed 19859664 PubMed 33922247 PubMed 33525668 FDA Labels: Body Balance Male Balance CLUE.IO	CHEMBL23194 PubChem??spermine?? DB00127
targinine	nitric oxide synthase inhibitor	Phase 3	From PubMed: PubMed 11898507 PubMed 33621423 PubMed 9050817 CLUE.IO PubMed	CHEMBL256147 PubChem??targinine?? DB11815
triflusal	cyclooxygenase inhibitor, platelet aggregation inhibitor, thromboxane synthase inhibitor	Launched	From PubMed: PubMed 9617597 PubMed 16034926 PubMed 16939630 CLUE.IO drugs.com	CHEMBL1332032 PubChem??triflusal?? DB08814

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P35228}

Subcellular Locations ^{Source UniProt P35228}

Biological Processes ^{Source UniProt P35228}

KEGG hsa:4843 ^{Source UniProt P35228}

Reactome Pathways ^{Source UniProt P35228}

R-HSA-1222556, ROS and RNS production in phagocytes
R-HSA-392154, Nitric oxide stimulates guanylate cyclase
R-HSA-6785807, Interleukin-4 and Interleukin-13 signaling
R-HSA-9033241, Peroxisomal protein import
R-HSA-9636249, Inhibition of nitric oxide production

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
A66	PI3K inhibitor	Preclinical	From PubMed: PubMed 31500286 PubMed 32618686 PubMed 9851910 CLUE.IO	CHEMBL3218581 PubChem: 42636535
alpelisib	PI3K inhibitor	Launched	From PubMed: PubMed 31091374 PubMed 33246021 PubMed 34633783 From EMA: Piqray (PDF) CLUE.IO DailyMed	CHEMBL2396661 PubChem: 56649450 DB12015
AS-604850	PI3K inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL1231533 PubChem: 5287855 DB07503
AZD6482	PI3K inhibitor	Phase 1	From PubMed: PubMed 22906130 PubMed 26096765 PubMed 24372076 CLUE.IO ClinicalTrials	CHEMBL2165191 PubChem: 44137675 DB14980
AZD8835	PI3K inhibitor	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL3894518 PubChem: 76685059
BEBT-908	PI3K inhibitor	Preclinical	From PubMed: No search result CLUE.IO	PubChem: 59474330
BGT226	PI3K inhibitor	Phase 1/Phase 2	From PubMed: PubMed 31190275 PubMed 22357447 PubMed 24372076 CLUE.IO ClinicalTrials	CHEMBL3218578 PubChem: 11978790
buparlisib	PI3K inhibitor	Phase 3	From PubMed: PubMed 33717263 PubMed 25963424 PubMed 29430197 CLUE.IO ClinicalTrials	CHEMBL2017974 PubChem: 16654980 DB11666
caffeine	adenosine receptor antagonist, phosphodiesterase inhibitor	Launched	From PubMed: PubMed 30977054 PubMed 23075568 PubMed 28446037 From EMA: Gencebok (PDF) CLUE.IO FDA Orange Book: caffeine, caffeine citrate	CHEMBL113 PubChem: 2519 DB00201
CH5132799	PI3K inhibitor	Phase 1	From PubMed: PubMed 25231405 CLUE.IO ClinicalTrials	CHEMBL1684984 PubChem: 49784945 DB13051
copanlisib	PI3K inhibitor	Launched	From PubMed: PubMed 31643732 PubMed 32576028 PubMed 29999999 FDA Labels: ALIQOPA CLUE.IO DailyMed	CHEMBL3218576 PubChem: DB12483
duvelisib	PI3K inhibitor	Launched	From PubMed: PubMed 30371996 PubMed 31644131 PubMed 32292084 FDA Labels: Copiktra COPIKTRA From EMA: Copiktra (PDF) CLUE.IO DailyMed	CHEMBL3039502 PubChem: 50905713 DB11952
ETP-45658	PI3K inhibitor	Preclinical	From PubMed: No search result CLUE.IO	PubChem: 25229608
GDC-0077	PI3K inhibitor	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	PubChem: 124173720 DB15275
GDC-0084	mTOR inhibitor, PI3K inhibitor	Phase 2	From PubMed: PubMed 31937616 PubMed 32269051 CLUE.IO ClinicalTrials	CHEMBL3813842 PubChem: 57384863 DB15186
GDC-0349	Pim kinase inhibitor	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL2331680 PubChem: 59239165 DB13072
GDC-0941	PI3K inhibitor	Phase 2	From PubMed: PubMed 31020608 PubMed 24099279 PubMed 30185228 CLUE.IO ClinicalTrials	CHEMBL521851 PubChem: 17755052 DB11663
GDC-0980	mTOR inhibitor, PI3K inhibitor	Phase 2	From PubMed: PubMed 26787751 PubMed 25165011 PubMed 26951309 CLUE.IO ClinicalTrials	CHEMBL1922094 PubChem: 25254071 DB12180
GSK1059615	PI3K inhibitor	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL3544966 PubChem: 23582824 DB11962
GSK2126458	mTOR inhibitor, PI3K inhibitor	Phase 1	From PubMed: PubMed 26603258 PubMed 27450049 PubMed 21651476 CLUE.IO ClinicalTrials	CHEMBL1236962 PubChem: 25167777 DB12703
idelalisib	PI3K inhibitor	Launched	From PubMed: PubMed 30069634 PubMed 29999908 PubMed 31644147 FDA Labels: Zydelig From EMA: Zydelig (PDF) CLUE.IO FDA Orange Book: idelalisib	CHEMBL2216870 PubChem??idelalisib?? DB09054
LY294002	DNA dependent protein kinase inhibitor, mTOR inhibitor, phosphodiesterase inhibitor, PI3K inhibitor, PLK inhibitor	Preclinical	From PubMed: PubMed 30981885 PubMed 28176634 PubMed 8791418 CLUE.IO	CHEMBL98350 PubChem??LY294002?? DB02656
MLN0128	mTOR inhibitor	Phase 2	From PubMed: PubMed 29508246 PubMed 26800393 PubMed 28601972 CLUE.IO ClinicalTrials	CHEMBL3545097 PubChem??MLN0128?? DB11836
MLN1117	PI3K inhibitor	Phase 2	From PubMed: PubMed 30168905 PubMed 28490463 CLUE.IO ClinicalTrials	CHEMBL3935857 PubChem??MLN1117?? DB14935
NVP-BEZ235	mTOR inhibitor, PI3K inhibitor	Phase 3	From PubMed: PubMed 23215722 PubMed 30981885 PubMed 29604436 CLUE.IO Unexpected Source	CHEMBL1879463 PubChem??NVP-BEZ235?? DB11651
perifosine	AKT inhibitor	Phase 3	From PubMed: PubMed 23253151 PubMed 23931614 PubMed 20023422 CLUE.IO ClinicalTrials	PubChem??perifosine??
PF-04691502	mTOR inhibitor, PI3K inhibitor	Phase 2	From PubMed: PubMed 27103175 PubMed 24395457 PubMed 29067643 CLUE.IO ClinicalTrials	CHEMBL1234354 PubChem??PF-04691502?? DB11974
PF-05212384	mTOR inhibitor, PI3K inhibitor	Phase 2	From PubMed: PubMed 27103175 PubMed 25652454 PubMed 29067643 CLUE.IO ClinicalTrials	CHEMBL592445 PubChem??PF-05212384?? DB11896
PI-103	mTOR inhibitor, PI3K inhibitor	Preclinical	From PubMed: PubMed 21651476 PubMed 20685578 PubMed 20179189 CLUE.IO	CHEMBL573339 PubChem??PI-103??
PIK-293	PI3K inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL3182327 PubChem??PIK-293??
PIK-75	DNA protein kinase inhibitor, PI3K inhibitor	Preclinical	From PubMed: PubMed 25659107 CLUE.IO	CHEMBL393525 PubChem??PIK-75??
PP-121	protein tyrosine kinase inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL1081312 PubChem??PP-121?? DB08052
SB-2343	mTOR inhibitor, PI3K inhibitor	Phase 1	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL3393066 PubChem??SB-2343?? DB12986
taselisib	PI3K inhibitor	Phase 3	From PubMed: PubMed 33186740 PubMed 29604436 PubMed 33148674 CLUE.IO ClinicalTrials	CHEMBL2387080 PubChem??taselisib?? DB12108
TG100-115	PI3K inhibitor	Phase 1/Phase 2	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL230011 PubChem??TG100-115?? DB05552
torin-1	mTOR inhibitor	Preclinical	From PubMed: PubMed 35414025 CLUE.IO	CHEMBL1256459 PubChem??torin-1??
voxtalisib	mTOR inhibitor, PI3K inhibitor	Phase 2	From PubMed: PubMed 29604436 PubMed 29550382 PubMed 28417284 CLUE.IO ClinicalTrials	CHEMBL3545366 PubChem??voxtalisib?? DB12400
wortmannin	PI3K inhibitor	Preclinical	From PubMed: PubMed 30981885 PubMed 7667888 PubMed 26827608 CLUE.IO	CHEMBL428496 PubChem??wortmannin?? DB08059
WYE-125132	mTOR inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL61661 PubChem??WYE-125132??
XL147	PI3K inhibitor	Phase 2	From PubMed: PubMed 25528496 PubMed 28275119 PubMed 25840972 CLUE.IO ClinicalTrials	CHEMBL3218575 PubChem??XL147??
ZSTK-474	PI3K inhibitor	Phase 1/Phase 2	From PubMed: No search result CLUE.IO ClinicalTrials	CHEMBL586702 PubChem??ZSTK-474?? DB12904

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P42336}

Subcellular Locations ^{Source UniProt P42336}

Biological Processes ^{Source UniProt P42336}

KEGG hsa:5290 ^{Source UniProt P42336}

Reactome Pathways ^{Source UniProt P42336}

R-HSA-109704, PI3K Cascade
R-HSA-112399, IRS-mediated signalling
R-HSA-114604, GPVI-mediated activation cascade
R-HSA-1236382, Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
R-HSA-1250342, PI3K events in ERBB4 signaling
R-HSA-1257604, PIP3 activates AKT signaling
R-HSA-1433557, Signaling by SCF-KIT
R-HSA-1660499, Synthesis of PIPs at the plasma membrane
R-HSA-180292, GAB1 signalosome
R-HSA-1839117, Signaling by cytosolic FGFR1 fusion mutants
R-HSA-186763, Downstream signal transduction
R-HSA-1963642, PI3K events in ERBB2 signaling
R-HSA-198203, PI3K/AKT activation
R-HSA-201556, Signaling by ALK
R-HSA-202424, Downstream TCR signaling
R-HSA-2029485, Role of phospholipids in phagocytosis
R-HSA-210993, Tie2 Signaling
R-HSA-2219530, Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-2424491, DAP12 signaling
R-HSA-2730905, Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-373753, Nephrin family interactions
R-HSA-388841, Costimulation by the CD28 family
R-HSA-389357, CD28 dependent PI3K/Akt signaling
R-HSA-416476, G alpha (q) signalling events
R-HSA-4420097, VEGFA-VEGFR2 Pathway
R-HSA-512988, Interleukin-3, Interleukin-5 and GM-CSF signaling
R-HSA-5637810, Constitutive Signaling by EGFRvIII
R-HSA-5654689, PI-3K cascade:FGFR1
R-HSA-5654695, PI-3K cascade:FGFR2
R-HSA-5654710, PI-3K cascade:FGFR3
R-HSA-5654720, PI-3K cascade:FGFR4
R-HSA-5655253, Signaling by FGFR2 in disease
R-HSA-5655291, Signaling by FGFR4 in disease
R-HSA-5655302, Signaling by FGFR1 in disease
R-HSA-5673001, RAF/MAP kinase cascade
R-HSA-6811558, PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-8851907, MET activates PI3K/AKT signaling
R-HSA-8853334, Signaling by FGFR3 fusions in cancer
R-HSA-8853338, Signaling by FGFR3 point mutants in cancer
R-HSA-8853659, RET signaling
R-HSA-9009391, Extra-nuclear estrogen signaling
R-HSA-9013149, RAC1 GTPase cycle
R-HSA-9013404, RAC2 GTPase cycle
R-HSA-9027276, Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
R-HSA-9028335, Activated NTRK2 signals through PI3K
R-HSA-912526, Interleukin receptor SHC signaling
R-HSA-912631, Regulation of signaling by CBL
R-HSA-9603381, Activated NTRK3 signals through PI3K
R-HSA-9607240, FLT3 Signaling
R-HSA-9664565, Signaling by ERBB2 KD Mutants
R-HSA-9665348, Signaling by ERBB2 ECD mutants
R-HSA-9670439, Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
R-HSA-9673767, Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
R-HSA-9673770, Signaling by PDGFRA extracellular domain mutants
R-HSA-9703465, Signaling by FLT3 fusion proteins
R-HSA-9703648, Signaling by FLT3 ITD and TKD mutants
R-HSA-9725370, Signaling by ALK fusions and activated point mutants

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
OTX015	bromodomain inhibitor	Phase 1/Phase 2	From PubMed: PubMed 27063977 PubMed 26341814 PubMed 27063978 CLUE.IO ClinicalTrials	CHEMBL3581647 PubChem??OTX015?? DB15189
succinobucol	antioxidant	Phase 2/Phase 3	From PubMed: PubMed 19335281 PubMed 19373083 PubMed 20838206 CLUE.IO ClinicalTrials	CHEMBL83626 PubChem??succinobucol?? DB05399

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P19320}

Subcellular Locations ^{Source UniProt P19320}

Biological Processes ^{Source UniProt P19320}

KEGG hsa:7412 ^{Source UniProt P19320}

Reactome Pathways ^{Source UniProt P19320}

R-HSA-198933, Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-216083, Integrin cell surface interactions
R-HSA-6785807, Interleukin-4 and Interleukin-13 signaling
R-HSA-877300, Interferon gamma signaling

GeneCards UniProtKB DrugBank Target Search

Compound	MoA ⁱ	Clinical Status	Resources ⁱ	DrugBank/PubChem/ ChEMBL
MK-1775	WEE1 kinase inhibitor	Phase 2	From PubMed: PubMed 25964244 PubMed 32958072 PubMed 34269904 CLUE.IO ClinicalTrials	CHEMBL1976040 PubChem??MK-1775?? DB11740
PD-166285	SRC inhibitor	Preclinical	From PubMed: PubMed 20406171 CLUE.IO	CHEMBL49120 PubChem??PD-166285??
PD-407824	PKC inhibitor	Preclinical	From PubMed: No search result CLUE.IO	CHEMBL214253 PubChem??PD-407824?? DB04608

Maximum 10 best STRING interactions

NETWORK PARAMETERS:

the style of edges in the network: evidence;
network type: physical;
threshold of significance to include an interaction, a number between 0 and 1000: 900

Molecular Functions ^{Source UniProt P30291}

Subcellular Locations ^{Source UniProt P30291}

Biological Processes ^{Source UniProt P30291}

KEGG hsa:7465 ^{Source UniProt P30291}

Reactome Pathways ^{Source UniProt P30291}

R-HSA-156711, Polo-like kinase mediated events
R-HSA-69202, Cyclin E associated events during G1/S transition
R-HSA-69273, Cyclin A/B1/B2 associated events during G2/M transition
R-HSA-69478, G2/M DNA replication checkpoint
R-HSA-69656, Cyclin A:Cdk2-associated events at S phase entry
R-HSA-75035, Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
R-HSA-983231, Factors involved in megakaryocyte development and platelet production

Drug Targets - Has CLUE.IO Entries Created at 2023-01-02 21:31:22 UTC

SUMMARY :: Overview

SUMMARY :: Molecular Background

SUMMARY :: Compounds

CDK4 :: Compounds

CDK4 :: STRING

Maximum 10 best STRING interactions

CDK4 :: Molecular Functions / Subcellular Locations / Biological Processes

Molecular Functions Source UniProt P11802

Subcellular Locations Source UniProt P11802

Biological Processes Source UniProt P11802

CDK4 :: Pathways

KEGG hsa:1019 Source UniProt P11802

Reactome Pathways Source UniProt P11802

CDK6 :: Compounds

CDK6 :: STRING

Maximum 10 best STRING interactions

CDK6 :: Molecular Functions / Subcellular Locations / Biological Processes

Molecular Functions Source UniProt Q00534

Subcellular Locations Source UniProt Q00534

Biological Processes Source UniProt Q00534

CDK6 :: Pathways

KEGG hsa:1021 Source UniProt Q00534

Reactome Pathways Source UniProt Q00534

COL1A1 :: Compounds

COL1A1 :: STRING

Maximum 10 best STRING interactions

COL1A1 :: Molecular Functions / Subcellular Locations / Biological Processes

Molecular Functions Source UniProt P02452

Subcellular Locations Source UniProt P02452

Biological Processes Source UniProt P02452

COL1A1 :: Pathways

KEGG hsa:1277 Source UniProt P02452

Reactome Pathways Source UniProt P02452

EGF :: Compounds

EGF :: STRING

Maximum 10 best STRING interactions

EGF :: Molecular Functions / Subcellular Locations / Biological Processes

Molecular Functions Source UniProt P01133

Subcellular Locations Source UniProt P01133

Biological Processes Source UniProt P01133

EGF :: Pathways

KEGG hsa:1950 Source UniProt P01133

Reactome Pathways Source UniProt P01133

EGFR :: Compounds

EGFR :: STRING

Maximum 10 best STRING interactions

EGFR :: Molecular Functions / Subcellular Locations / Biological Processes

Molecular Functions Source UniProt P00533

Subcellular Locations Source UniProt P00533

Biological Processes Source UniProt P00533

EGFR :: Pathways

KEGG hsa:1956 Source UniProt P00533

Reactome Pathways Source UniProt P00533

ERBB3 :: Compounds

ERBB3 :: STRING

Maximum 10 best STRING interactions

ERBB3 :: Molecular Functions / Subcellular Locations / Biological Processes

Molecular Functions Source UniProt P21860

Subcellular Locations Source UniProt P21860

Biological Processes Source UniProt P21860

ERBB3 :: Pathways

KEGG hsa:2065 Source UniProt P21860

Reactome Pathways Source UniProt P21860

ITGA2 :: Compounds

ITGA2 :: STRING

Maximum 10 best STRING interactions

ITGA2 :: Molecular Functions / Subcellular Locations / Biological Processes

Molecular Functions Source UniProt P17301

Subcellular Locations Source UniProt P17301

Biological Processes Source UniProt P17301

ITGA2 :: Pathways

KEGG hsa:3673 Source UniProt P17301

Reactome Pathways Source UniProt P17301

ITGA5 :: Compounds

ITGA5 :: STRING

Maximum 10 best STRING interactions

ITGA5 :: Molecular Functions / Subcellular Locations / Biological Processes

Molecular Functions Source UniProt P08648

Subcellular Locations Source UniProt P08648

Drug Targets - Has CLUE.IO Entries ^{Created at 2023-01-02 21:31:22 UTC}

Molecular Functions ^{Source UniProt P11802}

Subcellular Locations ^{Source UniProt P11802}

Biological Processes ^{Source UniProt P11802}

KEGG hsa:1019 ^{Source UniProt P11802}

Reactome Pathways ^{Source UniProt P11802}

Molecular Functions ^{Source UniProt Q00534}

Subcellular Locations ^{Source UniProt Q00534}

Biological Processes ^{Source UniProt Q00534}

KEGG hsa:1021 ^{Source UniProt Q00534}

Reactome Pathways ^{Source UniProt Q00534}

Molecular Functions ^{Source UniProt P02452}

Subcellular Locations ^{Source UniProt P02452}

Biological Processes ^{Source UniProt P02452}

KEGG hsa:1277 ^{Source UniProt P02452}

Reactome Pathways ^{Source UniProt P02452}

Molecular Functions ^{Source UniProt P01133}

Subcellular Locations ^{Source UniProt P01133}

Biological Processes ^{Source UniProt P01133}

KEGG hsa:1950 ^{Source UniProt P01133}

Reactome Pathways ^{Source UniProt P01133}

Molecular Functions ^{Source UniProt P00533}

Subcellular Locations ^{Source UniProt P00533}

Biological Processes ^{Source UniProt P00533}

KEGG hsa:1956 ^{Source UniProt P00533}

Reactome Pathways ^{Source UniProt P00533}

Molecular Functions ^{Source UniProt P21860}

Subcellular Locations ^{Source UniProt P21860}

Biological Processes ^{Source UniProt P21860}

KEGG hsa:2065 ^{Source UniProt P21860}

Reactome Pathways ^{Source UniProt P21860}

Molecular Functions ^{Source UniProt P17301}

Subcellular Locations ^{Source UniProt P17301}

Biological Processes ^{Source UniProt P17301}

KEGG hsa:3673 ^{Source UniProt P17301}

Reactome Pathways ^{Source UniProt P17301}

Molecular Functions ^{Source UniProt P08648}

Subcellular Locations ^{Source UniProt P08648}

Biological Processes ^{Source UniProt P08648}

KEGG hsa:3678 ^{Source UniProt P08648}

Reactome Pathways ^{Source UniProt P08648}

Molecular Functions ^{Source UniProt P06756}

Subcellular Locations ^{Source UniProt P06756}

Biological Processes ^{Source UniProt P06756}

KEGG hsa:3685 ^{Source UniProt P06756}

Reactome Pathways ^{Source UniProt P06756}

Molecular Functions ^{Source UniProt P18084}

Subcellular Locations ^{Source UniProt P18084}

Biological Processes ^{Source UniProt P18084}

KEGG hsa:3693 ^{Source UniProt P18084}

Reactome Pathways ^{Source UniProt P18084}

Molecular Functions ^{Source UniProt O15550}

Subcellular Locations ^{Source UniProt O15550}

Biological Processes ^{Source UniProt O15550}

KEGG hsa:7403 ^{Source UniProt O15550}

Reactome Pathways ^{Source UniProt O15550}

Molecular Functions ^{Source UniProt G3V5T7}

Subcellular Locations ^{Source UniProt G3V5T7}

Biological Processes ^{Source UniProt G3V5T7}

KEGG ^{Source UniProt G3V5T7}

Reactome Pathways ^{Source UniProt G3V5T7}

Molecular Functions ^{Source UniProt P09382}

Subcellular Locations ^{Source UniProt P09382}

Biological Processes ^{Source UniProt P09382}

KEGG hsa:3956 ^{Source UniProt P09382}

Reactome Pathways ^{Source UniProt P09382}

Molecular Functions ^{Source UniProt Q00987}

Subcellular Locations ^{Source UniProt Q00987}

Biological Processes ^{Source UniProt Q00987}

KEGG hsa:4193 ^{Source UniProt Q00987}

Reactome Pathways ^{Source UniProt Q00987}

Molecular Functions ^{Source UniProt P09874}

Subcellular Locations ^{Source UniProt P09874}